{"nctId":"NCT03158285","briefTitle":"A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis","startDateStruct":{"date":"2017-07-12","type":"ACTUAL"},"conditions":["Arthritis, Psoriatic"],"count":741,"armGroups":[{"label":"Group 1: Guselkumab","type":"EXPERIMENTAL","interventionNames":["Drug: Guselkumab"]},{"label":"Group 2: Guselkumab and Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Guselkumab","Drug: Placebo"]},{"label":"Group 3: Placebo Followed by Guselkumab","type":"EXPERIMENTAL","interventionNames":["Drug: Guselkumab","Drug: Placebo"]}],"interventions":[{"name":"Guselkumab","otherNames":["CNTO 1959"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a diagnosis of Psoriatic Arthritis (PsA) for at least 6 months before the first administration of study agent and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening\n* Have active PsA as defined by: at least 5 swollen joints and at least 5 tender joints at screening and at baseline, and CRP greater than or equal to (\\>=) 0.6 milligram per deciLitre (mg/dL) at screening from the central laboratory\n* Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis (confirmation of sacroiliitis should be performed at the screening visit by a locally performed pelvic x-ray \\[single anterior-posterior view\\] unless a pelvic or SI joint x-ray or pelvic magnetic resonance imaging (MRI) has been previously performed. Results must be documented)\n* Have active plaque psoriasis, with at least one psoriatic plaque of \\>= 2 centimeter (cm) diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis\n* Have active PsA despite previous non-biologic disease-modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy\n\nExclusion Criteria:\n\n* Has other inflammatory diseases that might confound the evaluations or benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease\n* Has previously received any biologic treatment\n* Has ever received tofacitinib, baricitinib, filgotinib, peficitinib (ASP015K), decernotinib (VX-509), or any other Janus kinase (JAK) inhibitor\n* Has received any systemic immunosuppressants (eg, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study agent\n* Is currently receiving 2 or more non-biologic DMARDs (other than methotrexate \\[MTX\\], sulfasalazine \\[SSZ\\], Hydroxychloroquine \\[HCQ\\], leflunomide \\[LEF\\]) including, but not limited to chloroquine, gold preparations, and penicillamine within 4 weeks before the first administration of study agent\n* Has received apremilast within 4 weeks prior to the first administration of study agent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24","description":"ACR 20 response: \\>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"64.1","spread":null},{"groupId":"OG002","value":"63.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24","description":"HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1300","spread":null},{"groupId":"OG001","value":"-0.3672","spread":null},{"groupId":"OG002","value":"-0.4004","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved an ACR 50 Response at Week 24","description":"ACR 50 response was defined as greater than or equal to (\\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"31.5","spread":null},{"groupId":"OG002","value":"33.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline","description":"A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \\>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"70.5","spread":null},{"groupId":"OG002","value":"68.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16","description":"ACR 20 response was defined as \\>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"55.2","spread":null},{"groupId":"OG002","value":"55.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":null},{"groupId":"OG001","value":"0.52","spread":null},{"groupId":"OG002","value":"0.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline","description":"Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\\>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"49.6","spread":null},{"groupId":"OG002","value":"44.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline","description":"The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \\>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","spread":null},{"groupId":"OG001","value":"59.4","spread":null},{"groupId":"OG002","value":"63.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline","description":"Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","spread":null},{"groupId":"OG001","value":"-1.52","spread":null},{"groupId":"OG002","value":"-1.59","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline","description":"The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.21","spread":null},{"groupId":"OG001","value":"-6.10","spread":null},{"groupId":"OG002","value":"-5.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":null},{"groupId":"OG001","value":"7.39","spread":null},{"groupId":"OG002","value":"7.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24","description":"The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":null},{"groupId":"OG001","value":"-1.59","spread":null},{"groupId":"OG002","value":"-1.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":null},{"groupId":"OG001","value":"4.17","spread":null},{"groupId":"OG002","value":"4.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16","description":"ACR 50 response was defined as \\>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"20.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24","description":"ACR 70 response was defined as \\>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"18.5","spread":null},{"groupId":"OG002","value":"13.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ACR 20 Response Through Week 24","description":"ACR 20 response was defined as \\>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"10.1","spread":null},{"groupId":"OG002","value":"10.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"19.8","spread":null},{"groupId":"OG002","value":"21.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"39.1","spread":null},{"groupId":"OG002","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":null},{"groupId":"OG001","value":"49.6","spread":null},{"groupId":"OG002","value":"51.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"55.2","spread":null},{"groupId":"OG002","value":"55.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":null},{"groupId":"OG001","value":"62.9","spread":null},{"groupId":"OG002","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"64.1","spread":null},{"groupId":"OG002","value":"63.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ACR 50 Response Through Week 24","description":"ACR 50 response was defined as \\>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"10.1","spread":null},{"groupId":"OG002","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"19.0","spread":null},{"groupId":"OG002","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"20.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"31.5","spread":null},{"groupId":"OG002","value":"29.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"31.5","spread":null},{"groupId":"OG002","value":"33.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ACR 70 Response Through Week 24","description":"ACR 70 response was defined as \\>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"8.1","spread":null},{"groupId":"OG002","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"13.7","spread":null},{"groupId":"OG002","value":"8.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"15.3","spread":null},{"groupId":"OG002","value":"13.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"18.5","spread":null},{"groupId":"OG002","value":"13.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24","description":"ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment (PGA) of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (milligram/deciliter \\[mg/dL\\]).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.9","spread":"32.16"},{"groupId":"OG001","value":"-18.8","spread":"39.68"},{"groupId":"OG002","value":"-18.5","spread":"38.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.1","spread":"37.29"},{"groupId":"OG001","value":"-30.5","spread":"36.92"},{"groupId":"OG002","value":"-33.6","spread":"37.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.4","spread":"39.03"},{"groupId":"OG001","value":"-46.8","spread":"40.68"},{"groupId":"OG002","value":"-46.7","spread":"37.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.1","spread":"41.20"},{"groupId":"OG001","value":"-57.6","spread":"39.22"},{"groupId":"OG002","value":"-58.3","spread":"35.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.6","spread":"43.01"},{"groupId":"OG001","value":"-64.1","spread":"35.46"},{"groupId":"OG002","value":"-63.7","spread":"34.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.2","spread":"41.70"},{"groupId":"OG001","value":"-69.3","spread":"33.63"},{"groupId":"OG002","value":"-71.4","spread":"30.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.9","spread":"45.54"},{"groupId":"OG001","value":"-71.3","spread":"34.06"},{"groupId":"OG002","value":"-73.1","spread":"30.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"25.99"},{"groupId":"OG001","value":"-10.4","spread":"40.31"},{"groupId":"OG002","value":"-14.8","spread":"28.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.1","spread":"36.04"},{"groupId":"OG001","value":"-15.0","spread":"41.57"},{"groupId":"OG002","value":"-22.6","spread":"32.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.9","spread":"37.83"},{"groupId":"OG001","value":"-31.0","spread":"42.36"},{"groupId":"OG002","value":"-33.8","spread":"37.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.4","spread":"37.57"},{"groupId":"OG001","value":"-40.9","spread":"42.73"},{"groupId":"OG002","value":"-43.0","spread":"35.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.6","spread":"41.87"},{"groupId":"OG001","value":"-47.0","spread":"40.96"},{"groupId":"OG002","value":"-48.1","spread":"37.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.9","spread":"44.22"},{"groupId":"OG001","value":"-53.9","spread":"37.83"},{"groupId":"OG002","value":"-54.2","spread":"35.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.3","spread":"44.87"},{"groupId":"OG001","value":"-54.2","spread":"37.15"},{"groupId":"OG002","value":"-57.3","spread":"34.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"35.794"},{"groupId":"OG001","value":"-8.92","spread":"32.374"},{"groupId":"OG002","value":"-4.66","spread":"32.229"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"35.849"},{"groupId":"OG001","value":"-12.58","spread":"33.065"},{"groupId":"OG002","value":"-7.96","spread":"37.958"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.76","spread":"34.213"},{"groupId":"OG001","value":"-21.61","spread":"36.705"},{"groupId":"OG002","value":"-17.05","spread":"44.783"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.01","spread":"36.061"},{"groupId":"OG001","value":"-26.26","spread":"40.223"},{"groupId":"OG002","value":"-25.91","spread":"37.862"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.70","spread":"41.673"},{"groupId":"OG001","value":"-31.94","spread":"42.882"},{"groupId":"OG002","value":"-27.85","spread":"38.913"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.85","spread":"46.497"},{"groupId":"OG001","value":"-35.16","spread":"39.471"},{"groupId":"OG002","value":"-35.35","spread":"39.016"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.84","spread":"48.324"},{"groupId":"OG001","value":"-38.06","spread":"40.565"},{"groupId":"OG002","value":"-36.52","spread":"38.423"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"35.882"},{"groupId":"OG001","value":"-10.15","spread":"31.060"},{"groupId":"OG002","value":"-5.25","spread":"32.658"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.27","spread":"34.291"},{"groupId":"OG001","value":"-12.71","spread":"34.440"},{"groupId":"OG002","value":"-11.02","spread":"33.605"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.51","spread":"35.908"},{"groupId":"OG001","value":"-21.58","spread":"33.697"},{"groupId":"OG002","value":"-19.13","spread":"40.545"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.30","spread":"37.185"},{"groupId":"OG001","value":"-27.86","spread":"38.900"},{"groupId":"OG002","value":"-28.33","spread":"34.058"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.34","spread":"39.207"},{"groupId":"OG001","value":"-32.25","spread":"40.056"},{"groupId":"OG002","value":"-28.60","spread":"39.759"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.52","spread":"42.498"},{"groupId":"OG001","value":"-35.31","spread":"36.205"},{"groupId":"OG002","value":"-35.11","spread":"37.791"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.87","spread":"45.650"},{"groupId":"OG001","value":"-37.05","spread":"38.372"},{"groupId":"OG002","value":"-34.13","spread":"51.445"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.79","spread":"25.687"},{"groupId":"OG001","value":"-15.06","spread":"27.150"},{"groupId":"OG002","value":"-13.85","spread":"23.307"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.63","spread":"27.573"},{"groupId":"OG001","value":"-23.72","spread":"27.658"},{"groupId":"OG002","value":"-22.32","spread":"28.183"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.29","spread":"28.416"},{"groupId":"OG001","value":"-36.54","spread":"31.224"},{"groupId":"OG002","value":"-37.99","spread":"29.970"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.63","spread":"32.379"},{"groupId":"OG001","value":"-46.54","spread":"30.489"},{"groupId":"OG002","value":"-42.84","spread":"31.305"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.11","spread":"32.023"},{"groupId":"OG001","value":"-52.02","spread":"31.915"},{"groupId":"OG002","value":"-49.18","spread":"31.383"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.13","spread":"36.576"},{"groupId":"OG001","value":"-54.32","spread":"30.941"},{"groupId":"OG002","value":"-54.59","spread":"29.336"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.59","spread":"33.740"},{"groupId":"OG001","value":"-57.22","spread":"32.480"},{"groupId":"OG002","value":"-58.70","spread":"28.255"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3191","spread":"36.62364"},{"groupId":"OG001","value":"-6.3577","spread":"50.81980"},{"groupId":"OG002","value":"-0.2385","spread":"57.44896"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8744","spread":"46.90795"},{"groupId":"OG001","value":"-9.1272","spread":"53.41051"},{"groupId":"OG002","value":"-5.1209","spread":"85.16625"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0965","spread":"39.89566"},{"groupId":"OG001","value":"-12.7684","spread":"67.23239"},{"groupId":"OG002","value":"-9.8081","spread":"86.78973"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0811","spread":"46.90093"},{"groupId":"OG001","value":"-18.0336","spread":"66.96524"},{"groupId":"OG002","value":"-17.7758","spread":"67.44643"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1776","spread":"48.33253"},{"groupId":"OG001","value":"-19.3627","spread":"70.83578"},{"groupId":"OG002","value":"-26.6732","spread":"53.14973"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4296","spread":"50.87958"},{"groupId":"OG001","value":"-24.9496","spread":"64.86820"},{"groupId":"OG002","value":"-28.9317","spread":"60.67279"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7995","spread":"54.78602"},{"groupId":"OG001","value":"-25.2578","spread":"63.15450"},{"groupId":"OG002","value":"-33.8837","spread":"51.59441"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.677","spread":"645.0281"},{"groupId":"OG001","value":"0.935","spread":"91.3783"},{"groupId":"OG002","value":"10.664","spread":"132.5947"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.042","spread":"208.6385"},{"groupId":"OG001","value":"-16.885","spread":"79.3501"},{"groupId":"OG002","value":"1.128","spread":"168.9301"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.451","spread":"322.4433"},{"groupId":"OG001","value":"-11.214","spread":"150.1689"},{"groupId":"OG002","value":"-17.474","spread":"112.3803"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.034","spread":"313.9875"},{"groupId":"OG001","value":"-25.620","spread":"97.1384"},{"groupId":"OG002","value":"-22.277","spread":"122.3489"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.595","spread":"237.6660"},{"groupId":"OG001","value":"-19.874","spread":"134.5210"},{"groupId":"OG002","value":"-26.592","spread":"86.8465"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.282","spread":"284.1330"},{"groupId":"OG001","value":"-13.551","spread":"193.3814"},{"groupId":"OG002","value":"-28.701","spread":"83.0912"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.263","spread":"149.5120"},{"groupId":"OG001","value":"-27.470","spread":"109.5239"},{"groupId":"OG002","value":"-28.125","spread":"87.7229"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24","description":"HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative changes from baseline indicate improvement of physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0594","spread":null},{"groupId":"OG001","value":"-0.1423","spread":null},{"groupId":"OG002","value":"-0.0795","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0722","spread":null},{"groupId":"OG001","value":"-0.1472","spread":null},{"groupId":"OG002","value":"-0.1605","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0942","spread":null},{"groupId":"OG001","value":"-0.2294","spread":null},{"groupId":"OG002","value":"-0.2336","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1332","spread":null},{"groupId":"OG001","value":"-0.2870","spread":null},{"groupId":"OG002","value":"-0.3010","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1167","spread":null},{"groupId":"OG001","value":"-0.3177","spread":null},{"groupId":"OG002","value":"-0.3442","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1565","spread":null},{"groupId":"OG001","value":"-0.3536","spread":null},{"groupId":"OG002","value":"-0.4019","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1300","spread":null},{"groupId":"OG001","value":"-0.3672","spread":null},{"groupId":"OG002","value":"-0.4004","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline","description":"HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":null},{"groupId":"OG001","value":"30.7","spread":null},{"groupId":"OG002","value":"23.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"32.0","spread":null},{"groupId":"OG002","value":"35.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"43.4","spread":null},{"groupId":"OG002","value":"42.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"47.4","spread":null},{"groupId":"OG002","value":"46.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"51.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null},{"groupId":"OG001","value":"48.7","spread":null},{"groupId":"OG002","value":"53.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"56.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24","description":"DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS 28 (CRP) response criteria was defined as follows: Good response: \\<=3.2 at visit and \\>1.2 improvement; Moderate response: \\>3.2 at visit and \\>1.2 improvement or \\<=5.1 at visit and \\>0.6-1.2 improvement; No response: \\<=0.6 improvement, or \\>5.1 at visit and \\<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder is defined as achieving a good or moderate DAS28 response at a specific visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"23.8","spread":null},{"groupId":"OG002","value":"24.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"38.7","spread":null},{"groupId":"OG002","value":"40.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null},{"groupId":"OG001","value":"56.9","spread":null},{"groupId":"OG002","value":"54.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null},{"groupId":"OG001","value":"67.3","spread":null},{"groupId":"OG002","value":"65.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null},{"groupId":"OG001","value":"69.8","spread":null},{"groupId":"OG002","value":"72.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"76.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"75.4","spread":null},{"groupId":"OG002","value":"80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24","description":"DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \\<2.6 at the analysis visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"5.2","spread":null},{"groupId":"OG002","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"10.5","spread":null},{"groupId":"OG002","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"14.1","spread":null},{"groupId":"OG002","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"18.5","spread":null},{"groupId":"OG002","value":"16.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"23.0","spread":null},{"groupId":"OG002","value":"21.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"24.6","spread":null},{"groupId":"OG002","value":"23.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24","description":"DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":null},{"groupId":"OG001","value":"-0.42","spread":null},{"groupId":"OG002","value":"-0.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":null},{"groupId":"OG001","value":"-0.62","spread":null},{"groupId":"OG002","value":"-0.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.59","spread":null},{"groupId":"OG001","value":"-0.99","spread":null},{"groupId":"OG002","value":"-0.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.85","spread":null},{"groupId":"OG001","value":"-1.27","spread":null},{"groupId":"OG002","value":"-1.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":null},{"groupId":"OG001","value":"-1.39","spread":null},{"groupId":"OG002","value":"-1.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":null},{"groupId":"OG001","value":"-1.52","spread":null},{"groupId":"OG002","value":"-1.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":null},{"groupId":"OG001","value":"-1.59","spread":null},{"groupId":"OG002","value":"-1.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24","description":"The modified PsARC response was defined as improvement in at least 2 of the four criteria: \\>=30% decrease in swollen joint count, \\>=30% decrease in tender joint count, \\>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \\>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"22.2","spread":null},{"groupId":"OG002","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null},{"groupId":"OG001","value":"32.7","spread":null},{"groupId":"OG002","value":"29.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":null},{"groupId":"OG001","value":"48.8","spread":null},{"groupId":"OG002","value":"50.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null},{"groupId":"OG001","value":"60.9","spread":null},{"groupId":"OG002","value":"60.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":null},{"groupId":"OG001","value":"66.5","spread":null},{"groupId":"OG002","value":"66.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"72.2","spread":null},{"groupId":"OG002","value":"69.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":null},{"groupId":"OG001","value":"72.6","spread":null},{"groupId":"OG002","value":"68.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline","description":"Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\\>0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"17.7","spread":null},{"groupId":"OG002","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"21.5","spread":null},{"groupId":"OG002","value":"25.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":null},{"groupId":"OG001","value":"31.0","spread":null},{"groupId":"OG002","value":"27.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":null},{"groupId":"OG001","value":"47.5","spread":null},{"groupId":"OG002","value":"40.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null},{"groupId":"OG001","value":"53.8","spread":null},{"groupId":"OG002","value":"43.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline","description":"The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \\>0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"13.5","spread":null},{"groupId":"OG002","value":"13.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"19.8","spread":null},{"groupId":"OG002","value":"20.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","spread":null},{"groupId":"OG001","value":"30.6","spread":null},{"groupId":"OG002","value":"31.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null},{"groupId":"OG001","value":"45.0","spread":null},{"groupId":"OG002","value":"52.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":null},{"groupId":"OG001","value":"56.8","spread":null},{"groupId":"OG002","value":"63.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline","description":"Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":null},{"groupId":"OG001","value":"-0.37","spread":null},{"groupId":"OG002","value":"-0.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":null},{"groupId":"OG001","value":"-0.56","spread":null},{"groupId":"OG002","value":"-0.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.67","spread":null},{"groupId":"OG001","value":"-0.92","spread":null},{"groupId":"OG002","value":"-0.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.94","spread":null},{"groupId":"OG001","value":"-1.37","spread":null},{"groupId":"OG002","value":"-1.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.03","spread":null},{"groupId":"OG001","value":"-1.60","spread":null},{"groupId":"OG002","value":"-1.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline","description":"The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":null},{"groupId":"OG001","value":"-1.11","spread":null},{"groupId":"OG002","value":"-0.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","spread":null},{"groupId":"OG001","value":"-2.11","spread":null},{"groupId":"OG002","value":"-1.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.17","spread":null},{"groupId":"OG001","value":"-3.17","spread":null},{"groupId":"OG002","value":"-3.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.40","spread":null},{"groupId":"OG001","value":"-4.88","spread":null},{"groupId":"OG002","value":"-4.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.03","spread":null},{"groupId":"OG001","value":"-5.95","spread":null},{"groupId":"OG002","value":"-5.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24","description":"PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \\[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \\[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \\[where 0= no tenderness and 3= extreme tenderness\\] and recoding to 0-1, where any score \\> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.863","spread":null},{"groupId":"OG001","value":"-1.452","spread":null},{"groupId":"OG002","value":"-1.413","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.158","spread":null},{"groupId":"OG001","value":"-2.110","spread":null},{"groupId":"OG002","value":"-1.994","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.336","spread":null},{"groupId":"OG001","value":"-2.403","spread":null},{"groupId":"OG002","value":"-2.399","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24","description":"GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \\[2.367\\*HAQ-DI\\]-\\[0.234\\*SF-PCS\\]-\\[0.244\\*SF-MCS\\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.029","spread":null},{"groupId":"OG001","value":"-2.326","spread":null},{"groupId":"OG002","value":"-2.214","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.198","spread":null},{"groupId":"OG001","value":"-2.593","spread":null},{"groupId":"OG002","value":"-2.589","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.553","spread":null},{"groupId":"OG001","value":"-3.451","spread":null},{"groupId":"OG002","value":"-4.717","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.491","spread":null},{"groupId":"OG001","value":"-3.103","spread":null},{"groupId":"OG002","value":"-3.827","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.281","spread":null},{"groupId":"OG001","value":"-16.054","spread":null},{"groupId":"OG002","value":"-15.083","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.157","spread":null},{"groupId":"OG001","value":"-19.366","spread":null},{"groupId":"OG002","value":"-19.492","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAi-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.232","spread":null},{"groupId":"OG001","value":"-15.926","spread":null},{"groupId":"OG002","value":"-15.808","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.869","spread":null},{"groupId":"OG001","value":"-19.711","spread":null},{"groupId":"OG002","value":"-20.023","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.569","spread":null},{"groupId":"OG001","value":"-17.107","spread":null},{"groupId":"OG002","value":"-17.029","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.320","spread":null},{"groupId":"OG001","value":"-21.467","spread":null},{"groupId":"OG002","value":"-20.480","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24","description":"The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":null},{"groupId":"OG001","value":"-2.39","spread":null},{"groupId":"OG002","value":"-2.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.30","spread":null},{"groupId":"OG001","value":"-2.94","spread":null},{"groupId":"OG002","value":"-3.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24","description":"DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \\<lower limit of quantification \\[LLOQ\\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6447","spread":null},{"groupId":"OG001","value":"-6.7838","spread":null},{"groupId":"OG002","value":"-6.3783","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6695","spread":null},{"groupId":"OG001","value":"-9.9687","spread":null},{"groupId":"OG002","value":"-10.2484","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4480","spread":null},{"groupId":"OG001","value":"-15.3303","spread":null},{"groupId":"OG002","value":"-15.8657","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.2915","spread":null},{"groupId":"OG001","value":"-18.9772","spread":null},{"groupId":"OG002","value":"-19.9687","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.8556","spread":null},{"groupId":"OG001","value":"-21.6939","spread":null},{"groupId":"OG002","value":"-21.4722","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.1375","spread":null},{"groupId":"OG001","value":"-23.3163","spread":null},{"groupId":"OG002","value":"-24.6844","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.8489","spread":null},{"groupId":"OG001","value":"-24.0359","spread":null},{"groupId":"OG002","value":"-25.1583","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24","description":"MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\\<=1, Swollen joint count (66 joints) \\<=1, Psoriasis activity and severity index \\<=1, Patient's Assessment of Pain \\<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \\<=20 on a 100-unit VAS, HAQ-DI score \\<=0.5, and Tender entheseal points \\<= 1 (LEI index score \\<= 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"16.9","spread":null},{"groupId":"OG002","value":"13.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"25.0","spread":null},{"groupId":"OG002","value":"18.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline","description":"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":null},{"groupId":"OG001","value":"46.3","spread":null},{"groupId":"OG002","value":"53.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":null},{"groupId":"OG001","value":"58.2","spread":null},{"groupId":"OG002","value":"69.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4","spread":null},{"groupId":"OG001","value":"59.7","spread":null},{"groupId":"OG002","value":"68.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"17.9","spread":null},{"groupId":"OG002","value":"18.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"37.3","spread":null},{"groupId":"OG002","value":"26.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":null},{"groupId":"OG001","value":"38.8","spread":null},{"groupId":"OG002","value":"37.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"11.9","spread":null},{"groupId":"OG002","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"23.9","spread":null},{"groupId":"OG002","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"20.9","spread":null},{"groupId":"OG002","value":"15.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.5","spread":null},{"groupId":"OG002","value":"3.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \\>=75% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"73.3","spread":null},{"groupId":"OG002","value":"73.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"79.0","spread":null},{"groupId":"OG002","value":"78.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \\>=90% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"55.1","spread":null},{"groupId":"OG002","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"68.8","spread":null},{"groupId":"OG002","value":"60.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"33.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"45.5","spread":null},{"groupId":"OG002","value":"44.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \\>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"38.6","spread":null},{"groupId":"OG002","value":"40.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"51.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.482","spread":null},{"groupId":"OG001","value":"-11.151","spread":null},{"groupId":"OG002","value":"-11.278","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.904","spread":null},{"groupId":"OG001","value":"-11.407","spread":null},{"groupId":"OG002","value":"-11.471","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"33.5","spread":null},{"groupId":"OG002","value":"26.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"51.3","spread":null},{"groupId":"OG002","value":"45.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"63.9","spread":null},{"groupId":"OG002","value":"59.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"71.2","spread":null},{"groupId":"OG002","value":"69.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null},{"groupId":"OG001","value":"79.5","spread":null},{"groupId":"OG002","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null},{"groupId":"OG001","value":"83.3","spread":null},{"groupId":"OG002","value":"86.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.653","spread":null},{"groupId":"OG001","value":"-6.818","spread":null},{"groupId":"OG002","value":"-6.396","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.410","spread":null},{"groupId":"OG001","value":"-8.545","spread":null},{"groupId":"OG002","value":"-8.147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.129","spread":null},{"groupId":"OG001","value":"-8.954","spread":null},{"groupId":"OG002","value":"-8.853","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \\>=75% improvement in PASI score from baseline. ACR 20: \\>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \\>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"48.9","spread":null},{"groupId":"OG002","value":"48.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"56.8","spread":null},{"groupId":"OG002","value":"57.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \\>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \\>=30% decrease in SJC and TJC, \\>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \\>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":null},{"groupId":"OG001","value":"56.8","spread":null},{"groupId":"OG002","value":"54.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"65.3","spread":null},{"groupId":"OG002","value":"60.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified vdH-S Erosion Score at Week 24","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":null},{"groupId":"OG001","value":"0.36","spread":null},{"groupId":"OG002","value":"0.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24","description":"The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the total JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 to 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. A positive change from baseline in the modified vdH-S JSN score indicates progression of joint space narrowing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null},{"groupId":"OG001","value":"0.16","spread":null},{"groupId":"OG002","value":"0.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"1.555"},{"groupId":"OG001","value":"0.18","spread":"1.280"},{"groupId":"OG002","value":"-0.03","spread":"1.514"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"1.106"},{"groupId":"OG001","value":"0.10","spread":"0.637"},{"groupId":"OG002","value":"0.08","spread":"0.607"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"2.441"},{"groupId":"OG001","value":"0.28","spread":"1.649"},{"groupId":"OG002","value":"0.05","spread":"1.881"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.801"},{"groupId":"OG001","value":"0.15","spread":"0.982"},{"groupId":"OG002","value":"0.14","spread":"0.894"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.516"},{"groupId":"OG001","value":"0.02","spread":"0.516"},{"groupId":"OG002","value":"0.07","spread":"0.632"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"1.116"},{"groupId":"OG001","value":"0.17","spread":"1.180"},{"groupId":"OG002","value":"0.21","spread":"1.210"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":null},{"groupId":"OG001","value":"63.5","spread":null},{"groupId":"OG002","value":"67.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"74.4","spread":null},{"groupId":"OG002","value":"78.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.8","spread":null},{"groupId":"OG001","value":"66.3","spread":null},{"groupId":"OG002","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"76.8","spread":null},{"groupId":"OG002","value":"80.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24","description":"The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. Change from baseline in the modified vdH-S JSN score \\<=0 (assessed by both readers) or \\<=0.5 (assessed by at least one reader) was considered as no progression of JSN.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null},{"groupId":"OG001","value":"78.8","spread":null},{"groupId":"OG002","value":"80.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"88.1","spread":null},{"groupId":"OG002","value":"88.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \\<=SDC of 2.18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":null},{"groupId":"OG001","value":"87.8","spread":null},{"groupId":"OG002","value":"89.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24","description":"Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC defined as the cut-off above which changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \\<=SDC of 1.83.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":null},{"groupId":"OG001","value":"89.0","spread":null},{"groupId":"OG002","value":"89.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24","description":"The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. The smallest detectable change (SDC) was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \\<=SDC of 1.11.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null},{"groupId":"OG001","value":"93.5","spread":null},{"groupId":"OG002","value":"91.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24","description":"Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.75","spread":null},{"groupId":"OG001","value":"4.83","spread":null},{"groupId":"OG002","value":"4.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.03","spread":null},{"groupId":"OG001","value":"6.65","spread":null},{"groupId":"OG002","value":"5.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":null},{"groupId":"OG001","value":"7.39","spread":null},{"groupId":"OG002","value":"7.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":null},{"groupId":"OG001","value":"2.28","spread":null},{"groupId":"OG002","value":"2.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":null},{"groupId":"OG001","value":"4.28","spread":null},{"groupId":"OG002","value":"3.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":null},{"groupId":"OG001","value":"4.17","spread":null},{"groupId":"OG002","value":"4.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.095","spread":null},{"groupId":"OG001","value":"3.879","spread":null},{"groupId":"OG002","value":"3.936","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.581","spread":null},{"groupId":"OG001","value":"6.124","spread":null},{"groupId":"OG002","value":"5.618","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.254","spread":null},{"groupId":"OG001","value":"6.703","spread":null},{"groupId":"OG002","value":"6.624","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.619","spread":null},{"groupId":"OG001","value":"3.599","spread":null},{"groupId":"OG002","value":"3.107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.965","spread":null},{"groupId":"OG001","value":"5.616","spread":null},{"groupId":"OG002","value":"4.942","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.365","spread":null},{"groupId":"OG001","value":"6.549","spread":null},{"groupId":"OG002","value":"6.241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.760","spread":null},{"groupId":"OG001","value":"5.456","spread":null},{"groupId":"OG002","value":"4.901","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.086","spread":null},{"groupId":"OG001","value":"7.485","spread":null},{"groupId":"OG002","value":"6.613","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.482","spread":null},{"groupId":"OG001","value":"7.811","spread":null},{"groupId":"OG002","value":"7.739","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.662","spread":null},{"groupId":"OG001","value":"4.111","spread":null},{"groupId":"OG002","value":"4.174","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.520","spread":null},{"groupId":"OG001","value":"5.719","spread":null},{"groupId":"OG002","value":"4.808","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.290","spread":null},{"groupId":"OG001","value":"5.794","spread":null},{"groupId":"OG002","value":"5.269","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.505","spread":null},{"groupId":"OG001","value":"4.286","spread":null},{"groupId":"OG002","value":"4.669","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.554","spread":null},{"groupId":"OG001","value":"6.967","spread":null},{"groupId":"OG002","value":"5.901","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.835","spread":null},{"groupId":"OG001","value":"7.373","spread":null},{"groupId":"OG002","value":"7.009","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.929","spread":null},{"groupId":"OG001","value":"3.337","spread":null},{"groupId":"OG002","value":"4.306","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.884","spread":null},{"groupId":"OG001","value":"5.584","spread":null},{"groupId":"OG002","value":"5.022","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.978","spread":null},{"groupId":"OG001","value":"5.806","spread":null},{"groupId":"OG002","value":"5.922","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.108","spread":null},{"groupId":"OG001","value":"2.459","spread":null},{"groupId":"OG002","value":"2.294","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.530","spread":null},{"groupId":"OG001","value":"4.497","spread":null},{"groupId":"OG002","value":"3.596","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.813","spread":null},{"groupId":"OG001","value":"4.382","spread":null},{"groupId":"OG002","value":"4.255","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.081","spread":null},{"groupId":"OG001","value":"2.380","spread":null},{"groupId":"OG002","value":"3.048","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.195","spread":null},{"groupId":"OG001","value":"4.529","spread":null},{"groupId":"OG002","value":"3.896","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.335","spread":null},{"groupId":"OG001","value":"4.490","spread":null},{"groupId":"OG002","value":"4.767","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":null},{"groupId":"OG001","value":"33.1","spread":null},{"groupId":"OG002","value":"27.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG001","value":"42.3","spread":null},{"groupId":"OG002","value":"31.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":null},{"groupId":"OG001","value":"37.5","spread":null},{"groupId":"OG002","value":"34.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null},{"groupId":"OG001","value":"45.2","spread":null},{"groupId":"OG002","value":"41.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":null},{"groupId":"OG001","value":"59.3","spread":null},{"groupId":"OG002","value":"51.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","spread":null},{"groupId":"OG001","value":"60.1","spread":null},{"groupId":"OG002","value":"55.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24","description":"The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \\[4 - score\\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.451","spread":null},{"groupId":"OG001","value":"5.031","spread":null},{"groupId":"OG002","value":"4.850","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.696","spread":null},{"groupId":"OG001","value":"6.977","spread":null},{"groupId":"OG002","value":"6.598","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.559","spread":null},{"groupId":"OG001","value":"7.550","spread":null},{"groupId":"OG002","value":"7.111","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24","description":"The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \\[4 - score\\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":null},{"groupId":"OG001","value":"56.0","spread":null},{"groupId":"OG002","value":"51.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4","spread":null},{"groupId":"OG001","value":"60.9","spread":null},{"groupId":"OG002","value":"56.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"60.5","spread":null},{"groupId":"OG002","value":"59.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS","description":"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.477","spread":null},{"groupId":"OG001","value":"17.496","spread":null},{"groupId":"OG002","value":"14.646","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.796","spread":null},{"groupId":"OG001","value":"18.371","spread":null},{"groupId":"OG002","value":"18.089","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index","description":"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health \"today\". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.058","spread":null},{"groupId":"OG001","value":"0.112","spread":null},{"groupId":"OG002","value":"0.101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.053","spread":null},{"groupId":"OG001","value":"0.115","spread":null},{"groupId":"OG002","value":"0.116","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52","description":"ACR 20 response was defined as \\>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":null},{"groupId":"OG001","value":"66.8","spread":null},{"groupId":"OG002","value":"66.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":null},{"groupId":"OG001","value":"71.2","spread":null},{"groupId":"OG002","value":"72.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null},{"groupId":"OG001","value":"77.7","spread":null},{"groupId":"OG002","value":"78.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null},{"groupId":"OG001","value":"79.7","spread":null},{"groupId":"OG002","value":"76.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.7","spread":null},{"groupId":"OG001","value":"79.1","spread":null},{"groupId":"OG002","value":"75.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52","description":"ACR 50 response was defined as \\>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null},{"groupId":"OG001","value":"32.8","spread":null},{"groupId":"OG002","value":"34.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"41.4","spread":null},{"groupId":"OG002","value":"40.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"44.1","spread":null},{"groupId":"OG002","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"48.3","spread":null},{"groupId":"OG002","value":"48.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":null},{"groupId":"OG001","value":"51.3","spread":null},{"groupId":"OG002","value":"49.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52","description":"ACR 70 response was defined as \\>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"19.3","spread":null},{"groupId":"OG002","value":"13.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"21.1","spread":null},{"groupId":"OG002","value":"21.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"24.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"29.9","spread":null},{"groupId":"OG002","value":"24.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":null},{"groupId":"OG001","value":"29.5","spread":null},{"groupId":"OG002","value":"28.1","spread":null}]}]}]},{"type":"SECONDARY","title":"ACR Components at Weeks 24, 28, 36, 44 and 52","description":"ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"6.99"},{"groupId":"OG001","value":"3.4","spread":"5.19"},{"groupId":"OG002","value":"4.1","spread":"5.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"5.17"},{"groupId":"OG001","value":"2.9","spread":"4.95"},{"groupId":"OG002","value":"3.2","spread":"5.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"3.77"},{"groupId":"OG001","value":"2.4","spread":"4.58"},{"groupId":"OG002","value":"2.7","spread":"4.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"3.19"},{"groupId":"OG001","value":"2.3","spread":"4.42"},{"groupId":"OG002","value":"2.8","spread":"5.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"3.59"},{"groupId":"OG001","value":"2.1","spread":"4.16"},{"groupId":"OG002","value":"2.5","spread":"4.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":"13.16"},{"groupId":"OG001","value":"9.1","spread":"9.94"},{"groupId":"OG002","value":"10.5","spread":"11.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"11.87"},{"groupId":"OG001","value":"7.9","spread":"9.02"},{"groupId":"OG002","value":"8.6","spread":"10.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"10.00"},{"groupId":"OG001","value":"7.0","spread":"8.72"},{"groupId":"OG002","value":"7.5","spread":"9.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"9.42"},{"groupId":"OG001","value":"6.3","spread":"8.45"},{"groupId":"OG002","value":"7.0","spread":"9.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"10.24"},{"groupId":"OG001","value":"6.2","spread":"8.18"},{"groupId":"OG002","value":"7.3","spread":"9.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.21","spread":"2.368"},{"groupId":"OG001","value":"3.77","spread":"2.457"},{"groupId":"OG002","value":"3.70","spread":"2.193"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.66","spread":"2.341"},{"groupId":"OG001","value":"3.50","spread":"2.311"},{"groupId":"OG002","value":"3.45","spread":"2.259"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.78","spread":"2.297"},{"groupId":"OG001","value":"3.28","spread":"2.336"},{"groupId":"OG002","value":"3.20","spread":"2.242"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.67","spread":"2.312"},{"groupId":"OG001","value":"3.22","spread":"2.370"},{"groupId":"OG002","value":"3.24","spread":"2.277"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.53","spread":"2.253"},{"groupId":"OG001","value":"3.10","spread":"2.333"},{"groupId":"OG002","value":"3.21","spread":"2.371"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.29","spread":"2.367"},{"groupId":"OG001","value":"4.01","spread":"2.516"},{"groupId":"OG002","value":"3.93","spread":"2.276"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.75","spread":"2.338"},{"groupId":"OG001","value":"3.76","spread":"2.348"},{"groupId":"OG002","value":"3.62","spread":"2.275"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.84","spread":"2.295"},{"groupId":"OG001","value":"3.52","spread":"2.390"},{"groupId":"OG002","value":"3.30","spread":"2.318"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.78","spread":"2.378"},{"groupId":"OG001","value":"3.36","spread":"2.447"},{"groupId":"OG002","value":"3.50","spread":"2.323"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","spread":"2.318"},{"groupId":"OG001","value":"3.23","spread":"2.383"},{"groupId":"OG002","value":"3.28","spread":"2.354"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","spread":"2.342"},{"groupId":"OG001","value":"2.74","spread":"2.113"},{"groupId":"OG002","value":"2.66","spread":"1.906"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.27","spread":"1.930"},{"groupId":"OG001","value":"2.44","spread":"1.941"},{"groupId":"OG002","value":"2.33","spread":"1.668"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":"1.594"},{"groupId":"OG001","value":"2.10","spread":"1.777"},{"groupId":"OG002","value":"2.06","spread":"1.716"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":"1.649"},{"groupId":"OG001","value":"1.97","spread":"1.842"},{"groupId":"OG002","value":"1.93","spread":"1.631"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.90","spread":"1.654"},{"groupId":"OG001","value":"1.77","spread":"1.645"},{"groupId":"OG002","value":"1.77","spread":"1.616"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1350","spread":"0.61984"},{"groupId":"OG001","value":"0.8766","spread":"0.59893"},{"groupId":"OG002","value":"0.8194","spread":"0.57287"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0457","spread":"0.59051"},{"groupId":"OG001","value":"0.8497","spread":"0.61863"},{"groupId":"OG002","value":"0.7985","spread":"0.56677"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9621","spread":"0.60695"},{"groupId":"OG001","value":"0.8091","spread":"0.61588"},{"groupId":"OG002","value":"0.7376","spread":"0.56257"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9117","spread":"0.63353"},{"groupId":"OG001","value":"0.7927","spread":"0.59979"},{"groupId":"OG002","value":"0.7804","spread":"0.57721"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9069","spread":"0.63695"},{"groupId":"OG001","value":"0.7917","spread":"0.59527"},{"groupId":"OG002","value":"0.7364","spread":"0.58655"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.543","spread":"2.1572"},{"groupId":"OG001","value":"0.961","spread":"1.2868"},{"groupId":"OG002","value":"0.790","spread":"0.8390"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.120","spread":"1.5140"},{"groupId":"OG001","value":"0.956","spread":"1.3749"},{"groupId":"OG002","value":"0.885","spread":"1.0299"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.920","spread":"1.4674"},{"groupId":"OG001","value":"0.892","spread":"1.3109"},{"groupId":"OG002","value":"0.837","spread":"1.0730"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.858","spread":"1.0558"},{"groupId":"OG001","value":"0.812","spread":"1.0139"},{"groupId":"OG002","value":"0.992","spread":"1.9875"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.907","spread":"1.5985"},{"groupId":"OG001","value":"0.937","spread":"1.2422"},{"groupId":"OG002","value":"0.910","spread":"1.2756"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52","description":"ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"7.25"},{"groupId":"OG001","value":"-8.2","spread":"6.09"},{"groupId":"OG002","value":"-8.8","spread":"5.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.1","spread":"6.99"},{"groupId":"OG001","value":"-8.8","spread":"5.98"},{"groupId":"OG002","value":"-9.6","spread":"6.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":"6.47"},{"groupId":"OG001","value":"-9.2","spread":"5.81"},{"groupId":"OG002","value":"-10.2","spread":"6.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"6.77"},{"groupId":"OG001","value":"-9.3","spread":"6.24"},{"groupId":"OG002","value":"-10.2","spread":"6.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.2","spread":"6.79"},{"groupId":"OG001","value":"-9.6","spread":"6.28"},{"groupId":"OG002","value":"-10.4","spread":"6.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":"10.91"},{"groupId":"OG001","value":"-10.4","spread":"9.51"},{"groupId":"OG002","value":"-11.9","spread":"9.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"10.78"},{"groupId":"OG001","value":"-11.7","spread":"9.24"},{"groupId":"OG002","value":"-13.7","spread":"10.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.2","spread":"10.78"},{"groupId":"OG001","value":"-12.5","spread":"9.68"},{"groupId":"OG002","value":"-14.6","spread":"10.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.0","spread":"11.02"},{"groupId":"OG001","value":"-13.3","spread":"9.56"},{"groupId":"OG002","value":"-15.2","spread":"10.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.1","spread":"11.39"},{"groupId":"OG001","value":"-13.4","spread":"10.03"},{"groupId":"OG002","value":"-15.0","spread":"10.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"2.441"},{"groupId":"OG001","value":"-2.55","spread":"2.477"},{"groupId":"OG002","value":"-2.41","spread":"2.335"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.63","spread":"2.420"},{"groupId":"OG001","value":"-2.83","spread":"2.519"},{"groupId":"OG002","value":"-2.66","spread":"2.416"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.51","spread":"2.588"},{"groupId":"OG001","value":"-3.02","spread":"2.534"},{"groupId":"OG002","value":"-2.89","spread":"2.540"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.62","spread":"2.640"},{"groupId":"OG001","value":"-3.07","spread":"2.644"},{"groupId":"OG002","value":"-2.87","spread":"2.601"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.75","spread":"2.659"},{"groupId":"OG001","value":"-3.20","spread":"2.555"},{"groupId":"OG002","value":"-2.89","spread":"2.681"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","spread":"2.601"},{"groupId":"OG001","value":"-2.52","spread":"2.490"},{"groupId":"OG002","value":"-2.40","spread":"2.383"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.79","spread":"2.543"},{"groupId":"OG001","value":"-2.79","spread":"2.560"},{"groupId":"OG002","value":"-2.70","spread":"2.382"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.70","spread":"2.555"},{"groupId":"OG001","value":"-2.99","spread":"2.569"},{"groupId":"OG002","value":"-3.01","spread":"2.445"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.76","spread":"2.741"},{"groupId":"OG001","value":"-3.15","spread":"2.650"},{"groupId":"OG002","value":"-2.86","spread":"2.559"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.85","spread":"2.757"},{"groupId":"OG001","value":"-3.29","spread":"2.558"},{"groupId":"OG002","value":"-3.06","spread":"2.527"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.45","spread":"2.248"},{"groupId":"OG001","value":"-3.84","spread":"2.316"},{"groupId":"OG002","value":"-3.93","spread":"2.227"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.42","spread":"2.189"},{"groupId":"OG001","value":"-4.16","spread":"2.175"},{"groupId":"OG002","value":"-4.28","spread":"2.054"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.39","spread":"2.052"},{"groupId":"OG001","value":"-4.49","spread":"2.116"},{"groupId":"OG002","value":"-4.53","spread":"2.173"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.61","spread":"2.043"},{"groupId":"OG001","value":"-4.55","spread":"2.139"},{"groupId":"OG002","value":"-4.70","spread":"2.084"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.77","spread":"2.007"},{"groupId":"OG001","value":"-4.78","spread":"1.996"},{"groupId":"OG002","value":"-4.81","spread":"2.120"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1646","spread":"0.53253"},{"groupId":"OG001","value":"-0.4044","spread":"0.54194"},{"groupId":"OG002","value":"-0.4257","spread":"0.50337"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2547","spread":"0.50426"},{"groupId":"OG001","value":"-0.4383","spread":"0.55648"},{"groupId":"OG002","value":"-0.4429","spread":"0.51556"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3423","spread":"0.52951"},{"groupId":"OG001","value":"-0.4702","spread":"0.55698"},{"groupId":"OG002","value":"-0.5000","spread":"0.55438"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3868","spread":"0.57065"},{"groupId":"OG001","value":"-0.4824","spread":"0.57091"},{"groupId":"OG002","value":"-0.4652","spread":"0.56121"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3848","spread":"0.58049"},{"groupId":"OG001","value":"-0.4824","spread":"0.56167"},{"groupId":"OG002","value":"-0.5082","spread":"0.58255"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.547","spread":"2.5657"},{"groupId":"OG001","value":"-1.038","spread":"2.0932"},{"groupId":"OG002","value":"-1.052","spread":"2.1295"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.993","spread":"2.3669"},{"groupId":"OG001","value":"-1.028","spread":"2.0476"},{"groupId":"OG002","value":"-0.976","spread":"2.1663"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.202","spread":"2.3234"},{"groupId":"OG001","value":"-1.098","spread":"2.1102"},{"groupId":"OG002","value":"-1.020","spread":"2.1985"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.262","spread":"2.5377"},{"groupId":"OG001","value":"-1.145","spread":"2.1378"},{"groupId":"OG002","value":"-0.861","spread":"2.8133"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.237","spread":"2.8242"},{"groupId":"OG001","value":"-1.021","spread":"2.2289"},{"groupId":"OG002","value":"-0.937","spread":"2.4116"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52","description":"ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.44","spread":"45.655"},{"groupId":"OG001","value":"-72.06","spread":"33.971"},{"groupId":"OG002","value":"-73.17","spread":"30.614"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.15","spread":"37.305"},{"groupId":"OG001","value":"-78.02","spread":"30.197"},{"groupId":"OG002","value":"-78.85","spread":"28.109"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-80.38","spread":"28.144"},{"groupId":"OG001","value":"-82.82","spread":"26.054"},{"groupId":"OG002","value":"-81.49","spread":"27.338"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-81.85","spread":"26.328"},{"groupId":"OG001","value":"-82.10","spread":"27.742"},{"groupId":"OG002","value":"-83.32","spread":"24.289"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.34","spread":"30.494"},{"groupId":"OG001","value":"-83.18","spread":"30.121"},{"groupId":"OG002","value":"-84.07","spread":"24.070"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.53","spread":"44.850"},{"groupId":"OG001","value":"-54.81","spread":"37.134"},{"groupId":"OG002","value":"-57.11","spread":"35.073"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.52","spread":"41.132"},{"groupId":"OG001","value":"-62.48","spread":"32.820"},{"groupId":"OG002","value":"-64.31","spread":"31.767"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.21","spread":"34.292"},{"groupId":"OG001","value":"-66.12","spread":"32.829"},{"groupId":"OG002","value":"-68.50","spread":"30.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-65.88","spread":"33.344"},{"groupId":"OG001","value":"-70.90","spread":"29.688"},{"groupId":"OG002","value":"-72.10","spread":"27.670"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.29","spread":"35.583"},{"groupId":"OG001","value":"-70.29","spread":"31.985"},{"groupId":"OG002","value":"-69.82","spread":"32.122"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.52","spread":"48.647"},{"groupId":"OG001","value":"-38.44","spread":"40.734"},{"groupId":"OG002","value":"-36.64","spread":"38.086"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.20","spread":"42.404"},{"groupId":"OG001","value":"-42.17","spread":"41.660"},{"groupId":"OG002","value":"-41.02","spread":"39.624"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.65","spread":"43.207"},{"groupId":"OG001","value":"-45.89","spread":"40.125"},{"groupId":"OG002","value":"-43.29","spread":"44.442"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.45","spread":"43.534"},{"groupId":"OG001","value":"-46.48","spread":"41.725"},{"groupId":"OG002","value":"-43.60","spread":"42.560"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.23","spread":"47.430"},{"groupId":"OG001","value":"-49.00","spread":"39.082"},{"groupId":"OG002","value":"-43.51","spread":"45.742"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.78","spread":"45.943"},{"groupId":"OG001","value":"-37.18","spread":"38.628"},{"groupId":"OG002","value":"-33.90","spread":"51.672"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.78","spread":"40.895"},{"groupId":"OG001","value":"-39.92","spread":"40.228"},{"groupId":"OG002","value":"-40.70","spread":"36.587"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.82","spread":"37.114"},{"groupId":"OG001","value":"-44.21","spread":"36.982"},{"groupId":"OG002","value":"-45.52","spread":"38.659"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.45","spread":"43.993"},{"groupId":"OG001","value":"-46.64","spread":"38.228"},{"groupId":"OG002","value":"-42.45","spread":"39.243"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.34","spread":"44.933"},{"groupId":"OG001","value":"-48.73","spread":"38.925"},{"groupId":"OG002","value":"-45.50","spread":"40.653"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.13","spread":"33.383"},{"groupId":"OG001","value":"-57.60","spread":"32.634"},{"groupId":"OG002","value":"-59.06","spread":"28.137"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.72","spread":"30.129"},{"groupId":"OG001","value":"-62.89","spread":"28.027"},{"groupId":"OG002","value":"-64.14","spread":"25.784"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-64.57","spread":"25.695"},{"groupId":"OG001","value":"-67.98","spread":"25.989"},{"groupId":"OG002","value":"-67.74","spread":"28.029"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-68.32","spread":"25.560"},{"groupId":"OG001","value":"-69.79","spread":"26.949"},{"groupId":"OG002","value":"-70.27","spread":"24.516"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.05","spread":"25.056"},{"groupId":"OG001","value":"-73.09","spread":"24.133"},{"groupId":"OG002","value":"-72.46","spread":"24.485"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.86","spread":"54.753"},{"groupId":"OG001","value":"-25.47","spread":"63.639"},{"groupId":"OG002","value":"-33.72","spread":"51.766"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.66","spread":"49.522"},{"groupId":"OG001","value":"-28.82","spread":"73.930"},{"groupId":"OG002","value":"-33.91","spread":"59.310"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.34","spread":"46.393"},{"groupId":"OG001","value":"-31.95","spread":"78.348"},{"groupId":"OG002","value":"-37.74","spread":"56.329"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.01","spread":"49.683"},{"groupId":"OG001","value":"-33.84","spread":"60.164"},{"groupId":"OG002","value":"-32.45","spread":"72.337"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.83","spread":"54.380"},{"groupId":"OG001","value":"-33.49","spread":"63.823"},{"groupId":"OG002","value":"-35.02","spread":"65.765"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.81","spread":"150.274"},{"groupId":"OG001","value":"-26.90","spread":"110.466"},{"groupId":"OG002","value":"-28.35","spread":"88.038"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":"155.637"},{"groupId":"OG001","value":"-21.09","spread":"144.287"},{"groupId":"OG002","value":"15.69","spread":"468.613"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.70","spread":"183.299"},{"groupId":"OG001","value":"-25.47","spread":"157.839"},{"groupId":"OG002","value":"-23.97","spread":"104.641"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"143.843"},{"groupId":"OG001","value":"-37.54","spread":"76.302"},{"groupId":"OG002","value":"-17.44","spread":"127.594"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"208.267"},{"groupId":"OG001","value":"-23.15","spread":"104.461"},{"groupId":"OG002","value":"-0.99","spread":"193.429"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24","description":"ACR 20 response was defined as \\>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"86.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24","description":"ACR 50 response was defined as \\>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24","description":"ACR 70 response was defined as \\>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \\[mm\\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52","description":"HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1646","spread":"0.53253"},{"groupId":"OG001","value":"-0.4044","spread":"0.54194"},{"groupId":"OG002","value":"-0.4257","spread":"0.50337"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2547","spread":"0.50426"},{"groupId":"OG001","value":"-0.4383","spread":"0.55648"},{"groupId":"OG002","value":"-0.4429","spread":"0.51556"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3423","spread":"0.52951"},{"groupId":"OG001","value":"-0.4702","spread":"0.55698"},{"groupId":"OG002","value":"-0.5000","spread":"0.55438"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3868","spread":"0.57065"},{"groupId":"OG001","value":"-0.4824","spread":"0.57091"},{"groupId":"OG002","value":"-0.4652","spread":"0.56121"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3848","spread":"0.58049"},{"groupId":"OG001","value":"-0.4824","spread":"0.56167"},{"groupId":"OG002","value":"-0.5082","spread":"0.58255"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline","description":"HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"52.5","spread":null},{"groupId":"OG002","value":"58.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4","spread":null},{"groupId":"OG001","value":"58.4","spread":null},{"groupId":"OG002","value":"63.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":null},{"groupId":"OG001","value":"58.2","spread":null},{"groupId":"OG002","value":"61.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"61.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"60.9","spread":null},{"groupId":"OG002","value":"62.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24","description":"HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null},{"groupId":"OG001","value":"88.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52","description":"DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \\<=3.2 at visit and \\>1.2 improvement; Moderate response: \\>3.2 at visit and \\>1.2 improvement or \\<=5.1 at visit and \\>0.6-1.2 improvement; No response: \\<=0.6 improvement, or \\>5.1 at visit and \\<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"79.0","spread":null},{"groupId":"OG002","value":"83.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":null},{"groupId":"OG001","value":"85.0","spread":null},{"groupId":"OG002","value":"85.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null},{"groupId":"OG001","value":"86.9","spread":null},{"groupId":"OG002","value":"92.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null},{"groupId":"OG001","value":"91.8","spread":null},{"groupId":"OG002","value":"91.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.0","spread":null},{"groupId":"OG001","value":"89.7","spread":null},{"groupId":"OG002","value":"89.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52","description":"DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \\<2.6 at the analysis visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"25.6","spread":null},{"groupId":"OG002","value":"24.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"27.5","spread":null},{"groupId":"OG002","value":"30.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"36.0","spread":null},{"groupId":"OG002","value":"39.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"38.4","spread":null},{"groupId":"OG002","value":"38.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.2","spread":null},{"groupId":"OG001","value":"39.7","spread":null},{"groupId":"OG002","value":"39.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52","description":"DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","spread":"1.101"},{"groupId":"OG001","value":"-1.63","spread":"1.051"},{"groupId":"OG002","value":"-1.68","spread":"0.976"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.38","spread":"1.099"},{"groupId":"OG001","value":"-1.78","spread":"1.038"},{"groupId":"OG002","value":"-1.86","spread":"1.066"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.92","spread":"1.086"},{"groupId":"OG001","value":"-1.97","spread":"1.114"},{"groupId":"OG002","value":"-2.08","spread":"1.088"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"1.098"},{"groupId":"OG001","value":"-2.09","spread":"1.107"},{"groupId":"OG002","value":"-2.08","spread":"1.063"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.14","spread":"1.142"},{"groupId":"OG001","value":"-2.08","spread":"1.121"},{"groupId":"OG002","value":"-2.11","spread":"1.128"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52","description":"The modified PsARC response was defined as improvement in at least 2 of the four criteria: \\>=30% decrease in swollen joint count, \\>=30% decrease in tender joint count, \\>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \\>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":null},{"groupId":"OG001","value":"76.4","spread":null},{"groupId":"OG002","value":"72.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":null},{"groupId":"OG001","value":"79.3","spread":null},{"groupId":"OG002","value":"83.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null},{"groupId":"OG001","value":"82.3","spread":null},{"groupId":"OG002","value":"84.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"83.7","spread":null},{"groupId":"OG002","value":"82.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"86.3","spread":null},{"groupId":"OG002","value":"82.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline","description":"Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\\>0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6","spread":null},{"groupId":"OG001","value":"57.6","spread":null},{"groupId":"OG002","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.3","spread":null},{"groupId":"OG001","value":"65.5","spread":null},{"groupId":"OG002","value":"60.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline","description":"Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.66"},{"groupId":"OG001","value":"-1.6","spread":"1.75"},{"groupId":"OG002","value":"-1.6","spread":"1.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.61"},{"groupId":"OG001","value":"-1.9","spread":"1.65"},{"groupId":"OG002","value":"-2.0","spread":"1.78"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline","description":"The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \\>0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null},{"groupId":"OG001","value":"60.7","spread":null},{"groupId":"OG002","value":"68.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":null},{"groupId":"OG001","value":"81.9","spread":null},{"groupId":"OG002","value":"81.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline","description":"The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"7.88"},{"groupId":"OG001","value":"-6.1","spread":"7.83"},{"groupId":"OG002","value":"-6.6","spread":"7.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"9.18"},{"groupId":"OG001","value":"-7.3","spread":"9.74"},{"groupId":"OG002","value":"-7.4","spread":"8.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52","description":"PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \\[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \\[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \\[where 0= no tenderness and 3= extreme tenderness\\] and recoding to 0-1, where any score \\> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.399","spread":"1.3169"},{"groupId":"OG001","value":"-2.496","spread":"1.5024"},{"groupId":"OG002","value":"-2.506","spread":"1.2578"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.041","spread":"1.4979"},{"groupId":"OG001","value":"-3.197","spread":"1.5212"},{"groupId":"OG002","value":"-3.161","spread":"1.4646"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52","description":"PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \\[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \\[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \\[where 0= no tenderness and 3= extreme tenderness\\] and recoding to 0-1, where any score \\> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"31.6","spread":null},{"groupId":"OG002","value":"24.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":null},{"groupId":"OG001","value":"45.3","spread":null},{"groupId":"OG002","value":"46.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52","description":"GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \\[2.367\\*HAQ-DI\\] - \\[0.234\\*SF-PCS\\] - \\[0.244\\*SF-MCS\\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.260","spread":"1.4909"},{"groupId":"OG001","value":"-2.658","spread":"1.6770"},{"groupId":"OG002","value":"-2.672","spread":"1.4589"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.085","spread":"1.6277"},{"groupId":"OG001","value":"-3.271","spread":"1.6453"},{"groupId":"OG002","value":"-3.267","spread":"1.5646"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52","description":"GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \\[2.367\\*HAQ-DI\\]-\\[0.234\\*SF-PCS\\]-\\[0.244\\*SF-MCS\\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \\<=2.3 at the analysis visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"29.5","spread":null},{"groupId":"OG002","value":"27.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":null},{"groupId":"OG001","value":"43.2","spread":null},{"groupId":"OG002","value":"43.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52","description":"DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.377","spread":"19.1814"},{"groupId":"OG001","value":"-24.718","spread":"16.7967"},{"groupId":"OG002","value":"-26.578","spread":"15.3393"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.199","spread":"17.9394"},{"groupId":"OG001","value":"-26.573","spread":"15.5254"},{"groupId":"OG002","value":"-29.613","spread":"17.6129"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.251","spread":"18.1137"},{"groupId":"OG001","value":"-28.889","spread":"16.4372"},{"groupId":"OG002","value":"-31.782","spread":"16.7698"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.754","spread":"18.5016"},{"groupId":"OG001","value":"-30.108","spread":"16.6013"},{"groupId":"OG002","value":"-32.126","spread":"15.7605"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.209","spread":"18.9981"},{"groupId":"OG001","value":"-30.512","spread":"17.5074"},{"groupId":"OG002","value":"-32.282","spread":"16.6320"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52","description":"The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.34","spread":"2.144"},{"groupId":"OG001","value":"-2.97","spread":"2.382"},{"groupId":"OG002","value":"-3.32","spread":"2.098"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.75","spread":"2.391"},{"groupId":"OG001","value":"-3.84","spread":"2.449"},{"groupId":"OG002","value":"-4.10","spread":"2.387"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52","description":"The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \\<=3.2 at the analysis visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"48.9","spread":null},{"groupId":"OG002","value":"43.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null},{"groupId":"OG001","value":"61.1","spread":null},{"groupId":"OG002","value":"60.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52","description":"MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\\<=1, Swollen joint count (66 joints) \\<=1, Psoriasis activity and severity index \\<=1, Patient's Assessment of Pain \\<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \\<=20 on a 100-unit VAS, HAQ-DI score \\<=0.5, and Tender entheseal points \\<= 1 (LEI index score \\<= 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"26.5","spread":null},{"groupId":"OG002","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"32.9","spread":null},{"groupId":"OG002","value":"36.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52","description":"A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \\<=1; swollen joint count \\<=1; PASI \\<=1; patient pain VAS score of \\<=15; patient global disease activity VAS \\[arthritis and psoriasis\\] score of \\<=20; Health Assessment Questionnaire (HAQ) score \\<=0.5; and tender entheseal points \\<=1) at that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"4.6","spread":null},{"groupId":"OG002","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"17.1","spread":null},{"groupId":"OG002","value":"12.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline","description":"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.374","spread":"2.4269"},{"groupId":"OG001","value":"-2.652","spread":"2.3825"},{"groupId":"OG002","value":"-2.674","spread":"1.9941"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.986","spread":"2.4945"},{"groupId":"OG001","value":"-2.883","spread":"2.5193"},{"groupId":"OG002","value":"-3.084","spread":"2.1843"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline","description":"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":null},{"groupId":"OG001","value":"62.5","spread":null},{"groupId":"OG002","value":"73.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":null},{"groupId":"OG001","value":"70.3","spread":null},{"groupId":"OG002","value":"79.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"40.6","spread":null},{"groupId":"OG002","value":"39.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"42.2","spread":null},{"groupId":"OG002","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null},{"groupId":"OG001","value":"21.9","spread":null},{"groupId":"OG002","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"26.6","spread":null},{"groupId":"OG002","value":"30.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"10.9","spread":null},{"groupId":"OG002","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.989","spread":"6.1515"},{"groupId":"OG001","value":"-11.685","spread":"12.3496"},{"groupId":"OG002","value":"-12.574","spread":"11.8391"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.016","spread":"9.9801"},{"groupId":"OG001","value":"-11.977","spread":"12.0847"},{"groupId":"OG002","value":"-12.857","spread":"11.3052"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \\>=50% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null},{"groupId":"OG001","value":"94.8","spread":null},{"groupId":"OG002","value":"93.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null},{"groupId":"OG001","value":"97.1","spread":null},{"groupId":"OG002","value":"98.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \\>=75% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"80.8","spread":null},{"groupId":"OG002","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null},{"groupId":"OG001","value":"88.8","spread":null},{"groupId":"OG002","value":"91.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \\>=90% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"70.3","spread":null},{"groupId":"OG002","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null},{"groupId":"OG001","value":"77.1","spread":null},{"groupId":"OG002","value":"81.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"46.5","spread":null},{"groupId":"OG002","value":"46.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null},{"groupId":"OG001","value":"54.7","spread":null},{"groupId":"OG002","value":"61.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \\>=75% improvement in PASI score from baseline. ACR 20: \\>=20% improvement in SJC (66 joints)+TJC (68 joints) and \\>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"58.1","spread":null},{"groupId":"OG002","value":"59.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null},{"groupId":"OG001","value":"73.5","spread":null},{"groupId":"OG002","value":"69.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \\>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \\>=30% decrease in SJC and TJC, \\>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \\>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"66.9","spread":null},{"groupId":"OG002","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.9","spread":null},{"groupId":"OG001","value":"79.4","spread":null},{"groupId":"OG002","value":"76.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \\>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":null},{"groupId":"OG001","value":"72.1","spread":null},{"groupId":"OG002","value":"71.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"77.1","spread":null},{"groupId":"OG002","value":"84.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \\>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"51.2","spread":null},{"groupId":"OG002","value":"52.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.9","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"66.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"65.6","spread":null},{"groupId":"OG002","value":"61.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"68.6","spread":null},{"groupId":"OG002","value":"68.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null},{"groupId":"OG001","value":"85.4","spread":null},{"groupId":"OG002","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":null},{"groupId":"OG001","value":"92.2","spread":null},{"groupId":"OG002","value":"89.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.142","spread":"6.4593"},{"groupId":"OG001","value":"-8.901","spread":"7.3657"},{"groupId":"OG002","value":"-9.249","spread":"7.0988"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.815","spread":"7.2714"},{"groupId":"OG001","value":"-9.235","spread":"7.3840"},{"groupId":"OG002","value":"-9.839","spread":"6.8777"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified vdH-S Score at Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"3.508"},{"groupId":"OG001","value":"0.97","spread":"3.623"},{"groupId":"OG002","value":"1.07","spread":"3.843"}]}]}]},{"type":"SECONDARY","title":"Change in Total Modified vdH-S Score From Week 24 to Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.635"},{"groupId":"OG001","value":"0.23","spread":"1.808"},{"groupId":"OG002","value":"0.62","spread":"2.530"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified vdH-S Erosion Score at Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"2.497"},{"groupId":"OG001","value":"0.67","spread":"2.707"},{"groupId":"OG002","value":"0.70","spread":"2.631"}]}]}]},{"type":"SECONDARY","title":"Change in Modified vdH-S Erosion Score From Week 24 to Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"1.277"},{"groupId":"OG001","value":"0.10","spread":"1.422"},{"groupId":"OG002","value":"0.39","spread":"1.725"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified vdH-S JSN Score at Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"1.356"},{"groupId":"OG001","value":"0.29","spread":"1.272"},{"groupId":"OG002","value":"0.38","spread":"1.633"}]}]}]},{"type":"SECONDARY","title":"Change in Modified vdH-S JSN Score From Week 24 to Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.635"},{"groupId":"OG001","value":"0.13","spread":"0.705"},{"groupId":"OG002","value":"0.23","spread":"1.088"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"1.815"},{"groupId":"OG001","value":"0.37","spread":"1.969"},{"groupId":"OG002","value":"0.35","spread":"1.830"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"1.181"},{"groupId":"OG001","value":"0.19","spread":"0.913"},{"groupId":"OG002","value":"0.22","spread":"1.235"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"2.706"},{"groupId":"OG001","value":"0.56","spread":"2.589"},{"groupId":"OG002","value":"0.57","spread":"2.759"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"1.014"},{"groupId":"OG001","value":"0.30","spread":"1.339"},{"groupId":"OG002","value":"0.34","spread":"1.413"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.353"},{"groupId":"OG001","value":"0.10","spread":"0.660"},{"groupId":"OG002","value":"0.16","spread":"0.864"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.220"},{"groupId":"OG001","value":"0.40","spread":"1.687"},{"groupId":"OG002","value":"0.50","spread":"1.939"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":null},{"groupId":"OG001","value":"55.7","spread":null},{"groupId":"OG002","value":"56.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","spread":null},{"groupId":"OG001","value":"67.2","spread":null},{"groupId":"OG002","value":"72.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null},{"groupId":"OG001","value":"59.6","spread":null},{"groupId":"OG002","value":"60.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4","spread":null},{"groupId":"OG001","value":"71.1","spread":null},{"groupId":"OG002","value":"72.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null},{"groupId":"OG001","value":"75.3","spread":null},{"groupId":"OG002","value":"79.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"86.0","spread":null},{"groupId":"OG002","value":"86.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \\<=SDC of 2.39.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"82.6","spread":null},{"groupId":"OG002","value":"85.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52","description":"Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \\<=SDC of 2.22.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.2","spread":null},{"groupId":"OG001","value":"84.3","spread":null},{"groupId":"OG002","value":"87.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52","description":"Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as cut-off above which changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in modified vdH-S JSN score \\<=SDC of 1.02.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null},{"groupId":"OG001","value":"91.5","spread":null},{"groupId":"OG002","value":"90.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52","description":"Percentage of Participants with Pencil in cup or Gross Osteolysis Deformities were reported. Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"4.6","spread":null},{"groupId":"OG002","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"5.1","spread":null},{"groupId":"OG002","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF-36 PCS Score at Weeks 24 and 52","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.782","spread":"7.1776"},{"groupId":"OG001","value":"7.838","spread":"8.0335"},{"groupId":"OG002","value":"7.183","spread":"6.9793"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.124","spread":"8.2192"},{"groupId":"OG001","value":"9.511","spread":"8.3176"},{"groupId":"OG002","value":"8.960","spread":"8.5891"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF-36 MCS Score at Weeks 24 and 52","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.211","spread":"10.1368"},{"groupId":"OG001","value":"4.452","spread":"9.9560"},{"groupId":"OG002","value":"4.128","spread":"9.1814"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.297","spread":"10.8960"},{"groupId":"OG001","value":"4.465","spread":"9.7780"},{"groupId":"OG002","value":"4.076","spread":"9.1101"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.602","spread":"7.7388"},{"groupId":"OG001","value":"7.052","spread":"8.5020"},{"groupId":"OG002","value":"6.772","spread":"7.5920"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.722","spread":"8.9480"},{"groupId":"OG001","value":"8.489","spread":"8.8599"},{"groupId":"OG002","value":"8.374","spread":"8.7884"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.695","spread":"7.5950"},{"groupId":"OG001","value":"6.897","spread":"7.7240"},{"groupId":"OG002","value":"6.381","spread":"7.2203"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.560","spread":"8.5399"},{"groupId":"OG001","value":"7.677","spread":"8.2995"},{"groupId":"OG002","value":"7.344","spread":"7.7145"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.882","spread":"8.3009"},{"groupId":"OG001","value":"8.333","spread":"8.3852"},{"groupId":"OG002","value":"7.833","spread":"7.3390"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.460","spread":"8.4659"},{"groupId":"OG001","value":"10.238","spread":"8.7185"},{"groupId":"OG002","value":"9.457","spread":"9.7977"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.255","spread":"7.2176"},{"groupId":"OG001","value":"5.963","spread":"7.8794"},{"groupId":"OG002","value":"5.067","spread":"7.4182"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.396","spread":"8.5589"},{"groupId":"OG001","value":"7.173","spread":"7.2703"},{"groupId":"OG002","value":"6.366","spread":"8.4199"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.224","spread":"9.0878"},{"groupId":"OG001","value":"7.914","spread":"9.4638"},{"groupId":"OG002","value":"6.970","spread":"9.4889"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.879","spread":"9.4160"},{"groupId":"OG001","value":"8.646","spread":"9.5131"},{"groupId":"OG002","value":"7.654","spread":"9.3905"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.088","spread":"10.4330"},{"groupId":"OG001","value":"6.551","spread":"9.7076"},{"groupId":"OG002","value":"5.892","spread":"8.5510"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.278","spread":"10.9444"},{"groupId":"OG001","value":"7.199","spread":"10.1315"},{"groupId":"OG002","value":"6.787","spread":"9.5326"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.910","spread":"10.0772"},{"groupId":"OG001","value":"4.535","spread":"10.1304"},{"groupId":"OG002","value":"4.107","spread":"8.9473"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.057","spread":"10.8795"},{"groupId":"OG001","value":"4.970","spread":"10.1685"},{"groupId":"OG002","value":"4.607","spread":"8.7627"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.583","spread":"9.2222"},{"groupId":"OG001","value":"4.605","spread":"9.7905"},{"groupId":"OG002","value":"4.752","spread":"8.9336"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.153","spread":"10.0724"},{"groupId":"OG001","value":"4.829","spread":"9.3665"},{"groupId":"OG002","value":"4.741","spread":"9.3825"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","spread":null},{"groupId":"OG001","value":"63.4","spread":null},{"groupId":"OG002","value":"58.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null},{"groupId":"OG001","value":"67.1","spread":null},{"groupId":"OG002","value":"65.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.5","spread":null},{"groupId":"OG001","value":"40.3","spread":null},{"groupId":"OG002","value":"36.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"44.9","spread":null},{"groupId":"OG002","value":"38.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52","description":"The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \\[4 - score\\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.844","spread":"9.0440"},{"groupId":"OG001","value":"8.034","spread":"9.8888"},{"groupId":"OG002","value":"6.970","spread":"8.6274"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.548","spread":"9.3745"},{"groupId":"OG001","value":"8.927","spread":"9.4646"},{"groupId":"OG002","value":"7.686","spread":"9.0833"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52","description":"The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \\[4 - score\\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":null},{"groupId":"OG001","value":"63.9","spread":null},{"groupId":"OG002","value":"62.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3","spread":null},{"groupId":"OG001","value":"69.7","spread":null},{"groupId":"OG002","value":"68.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS","description":"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.456","spread":"25.7204"},{"groupId":"OG001","value":"19.282","spread":"23.5220"},{"groupId":"OG002","value":"17.500","spread":"22.6981"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.474","spread":"25.5974"},{"groupId":"OG001","value":"23.295","spread":"23.6270"},{"groupId":"OG002","value":"19.983","spread":"24.7643"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index","description":"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health \"today\". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.060","spread":"0.1558"},{"groupId":"OG001","value":"0.124","spread":"0.1476"},{"groupId":"OG002","value":"0.117","spread":"0.1307"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.137","spread":"0.1605"},{"groupId":"OG001","value":"0.146","spread":"0.1587"},{"groupId":"OG002","value":"0.135","spread":"0.1469"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.64","spread":"28.355"},{"groupId":"OG001","value":"-3.77","spread":"28.029"},{"groupId":"OG002","value":"-1.20","spread":"17.127"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.37","spread":"25.365"},{"groupId":"OG001","value":"-4.47","spread":"20.454"},{"groupId":"OG002","value":"-1.74","spread":"17.084"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.14","spread":"29.027"},{"groupId":"OG001","value":"-21.28","spread":"25.621"},{"groupId":"OG002","value":"-20.08","spread":"22.084"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.27","spread":"31.502"},{"groupId":"OG001","value":"-27.93","spread":"25.263"},{"groupId":"OG002","value":"-22.10","spread":"26.172"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.42","spread":"29.916"},{"groupId":"OG001","value":"-21.68","spread":"27.065"},{"groupId":"OG002","value":"-20.90","spread":"22.814"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.06","spread":"32.092"},{"groupId":"OG001","value":"-28.19","spread":"25.536"},{"groupId":"OG002","value":"-22.24","spread":"26.920"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.80","spread":"26.131"},{"groupId":"OG001","value":"-23.03","spread":"25.559"},{"groupId":"OG002","value":"-21.07","spread":"21.493"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.13","spread":"27.436"},{"groupId":"OG001","value":"-27.14","spread":"25.657"},{"groupId":"OG002","value":"-26.11","spread":"25.361"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100","description":"ACR 20 response was defined as \\>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.7","spread":null},{"groupId":"OG001","value":"78.9","spread":null},{"groupId":"OG002","value":"77.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":null},{"groupId":"OG001","value":"85.2","spread":null},{"groupId":"OG002","value":"80.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":null},{"groupId":"OG001","value":"83.1","spread":null},{"groupId":"OG002","value":"82.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.1","spread":null},{"groupId":"OG001","value":"85.1","spread":null},{"groupId":"OG002","value":"80.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":null},{"groupId":"OG001","value":"82.1","spread":null},{"groupId":"OG002","value":"84.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100","description":"ACR 50 response was defined as \\>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":null},{"groupId":"OG001","value":"50.9","spread":null},{"groupId":"OG002","value":"49.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":null},{"groupId":"OG001","value":"60.8","spread":null},{"groupId":"OG002","value":"58.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"56.0","spread":null},{"groupId":"OG002","value":"58.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null},{"groupId":"OG001","value":"63.8","spread":null},{"groupId":"OG002","value":"57.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null},{"groupId":"OG001","value":"60.7","spread":null},{"groupId":"OG002","value":"62.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100","description":"ACR 70 response was defined as \\>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"29.7","spread":null},{"groupId":"OG002","value":"28.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"35.5","spread":null},{"groupId":"OG002","value":"36.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":null},{"groupId":"OG001","value":"36.4","spread":null},{"groupId":"OG002","value":"32.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"42.8","spread":null},{"groupId":"OG002","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":null},{"groupId":"OG001","value":"39.3","spread":null},{"groupId":"OG002","value":"38.6","spread":null}]}]}]},{"type":"SECONDARY","title":"ACR Components at Weeks 52, 68, 76, 84 and 100","description":"ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"3.58"},{"groupId":"OG001","value":"2.1","spread":"4.18"},{"groupId":"OG002","value":"2.5","spread":"4.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"3.10"},{"groupId":"OG001","value":"1.7","spread":"3.87"},{"groupId":"OG002","value":"2.0","spread":"3.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"3.17"},{"groupId":"OG001","value":"1.8","spread":"3.72"},{"groupId":"OG002","value":"2.3","spread":"4.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"3.02"},{"groupId":"OG001","value":"1.6","spread":"3.82"},{"groupId":"OG002","value":"2.0","spread":"5.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"3.75"},{"groupId":"OG001","value":"1.6","spread":"3.99"},{"groupId":"OG002","value":"2.0","spread":"4.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"10.30"},{"groupId":"OG001","value":"6.3","spread":"8.20"},{"groupId":"OG002","value":"7.2","spread":"9.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"8.83"},{"groupId":"OG001","value":"5.0","spread":"6.83"},{"groupId":"OG002","value":"6.3","spread":"9.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"8.31"},{"groupId":"OG001","value":"5.2","spread":"7.18"},{"groupId":"OG002","value":"6.2","spread":"8.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"7.32"},{"groupId":"OG001","value":"4.7","spread":"7.20"},{"groupId":"OG002","value":"5.9","spread":"9.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"8.44"},{"groupId":"OG001","value":"4.7","spread":"6.80"},{"groupId":"OG002","value":"6.0","spread":"8.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.53","spread":"2.267"},{"groupId":"OG001","value":"3.12","spread":"2.335"},{"groupId":"OG002","value":"3.17","spread":"2.343"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.26","spread":"2.313"},{"groupId":"OG001","value":"2.68","spread":"2.240"},{"groupId":"OG002","value":"2.64","spread":"2.105"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.17","spread":"2.271"},{"groupId":"OG001","value":"2.73","spread":"2.217"},{"groupId":"OG002","value":"2.70","spread":"2.115"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.97","spread":"2.150"},{"groupId":"OG001","value":"2.67","spread":"2.181"},{"groupId":"OG002","value":"2.65","spread":"2.217"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":"2.221"},{"groupId":"OG001","value":"2.59","spread":"2.290"},{"groupId":"OG002","value":"2.57","spread":"2.138"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","spread":"2.331"},{"groupId":"OG001","value":"3.25","spread":"2.380"},{"groupId":"OG002","value":"3.24","spread":"2.322"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.50","spread":"2.355"},{"groupId":"OG001","value":"2.95","spread":"2.282"},{"groupId":"OG002","value":"2.85","spread":"2.213"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.25","spread":"2.356"},{"groupId":"OG001","value":"2.90","spread":"2.273"},{"groupId":"OG002","value":"2.95","spread":"2.222"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.09","spread":"2.273"},{"groupId":"OG001","value":"2.88","spread":"2.252"},{"groupId":"OG002","value":"2.83","spread":"2.222"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.15","spread":"2.395"},{"groupId":"OG001","value":"2.85","spread":"2.378"},{"groupId":"OG002","value":"2.60","spread":"2.165"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"1.654"},{"groupId":"OG001","value":"1.78","spread":"1.647"},{"groupId":"OG002","value":"1.77","spread":"1.617"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":"1.514"},{"groupId":"OG001","value":"1.56","spread":"1.538"},{"groupId":"OG002","value":"1.61","spread":"1.466"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"1.469"},{"groupId":"OG001","value":"1.67","spread":"1.660"},{"groupId":"OG002","value":"1.57","spread":"1.524"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"1.492"},{"groupId":"OG001","value":"1.51","spread":"1.619"},{"groupId":"OG002","value":"1.50","spread":"1.558"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"1.510"},{"groupId":"OG001","value":"1.49","spread":"1.581"},{"groupId":"OG002","value":"1.41","spread":"1.405"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9073","spread":"0.63812"},{"groupId":"OG001","value":"0.7942","spread":"0.59711"},{"groupId":"OG002","value":"0.7317","spread":"0.58430"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8425","spread":"0.61757"},{"groupId":"OG001","value":"0.7625","spread":"0.59524"},{"groupId":"OG002","value":"0.6836","spread":"0.56049"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8311","spread":"0.62101"},{"groupId":"OG001","value":"0.6978","spread":"0.56588"},{"groupId":"OG002","value":"0.6996","spread":"0.55988"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8076","spread":"0.62465"},{"groupId":"OG001","value":"0.7134","spread":"0.59528"},{"groupId":"OG002","value":"0.6775","spread":"0.58870"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7692","spread":"0.59960"},{"groupId":"OG001","value":"0.6747","spread":"0.57213"},{"groupId":"OG002","value":"0.6420","spread":"0.56838"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.904","spread":"1.6039"},{"groupId":"OG001","value":"0.930","spread":"1.2443"},{"groupId":"OG002","value":"0.886","spread":"1.2366"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.861","spread":"1.1586"},{"groupId":"OG001","value":"0.884","spread":"1.3520"},{"groupId":"OG002","value":"0.796","spread":"1.1109"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.903","spread":"1.4624"},{"groupId":"OG001","value":"0.882","spread":"1.2504"},{"groupId":"OG002","value":"0.839","spread":"1.1693"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.898","spread":"1.3229"},{"groupId":"OG001","value":"0.856","spread":"1.1926"},{"groupId":"OG002","value":"0.872","spread":"1.3239"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.880","spread":"1.3415"},{"groupId":"OG001","value":"0.826","spread":"1.2277"},{"groupId":"OG002","value":"0.820","spread":"1.1227"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100","description":"ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.2","spread":"6.72"},{"groupId":"OG001","value":"-9.6","spread":"6.30"},{"groupId":"OG002","value":"-10.4","spread":"6.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.7","spread":"6.76"},{"groupId":"OG001","value":"-10.0","spread":"6.50"},{"groupId":"OG002","value":"-10.9","spread":"7.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.7","spread":"5.98"},{"groupId":"OG001","value":"-10.0","spread":"6.33"},{"groupId":"OG002","value":"-10.7","spread":"6.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"6.06"},{"groupId":"OG001","value":"-10.1","spread":"6.34"},{"groupId":"OG002","value":"-10.7","spread":"7.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"6.15"},{"groupId":"OG001","value":"-10.2","spread":"6.88"},{"groupId":"OG002","value":"-10.8","spread":"6.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.1","spread":"11.38"},{"groupId":"OG001","value":"-13.5","spread":"10.04"},{"groupId":"OG002","value":"-15.2","spread":"10.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.7","spread":"10.94"},{"groupId":"OG001","value":"-14.8","spread":"10.15"},{"groupId":"OG002","value":"-16.0","spread":"11.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.1","spread":"10.97"},{"groupId":"OG001","value":"-14.7","spread":"10.22"},{"groupId":"OG002","value":"-16.1","spread":"10.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.6","spread":"11.33"},{"groupId":"OG001","value":"-15.3","spread":"10.50"},{"groupId":"OG002","value":"-16.0","spread":"11.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.3","spread":"11.27"},{"groupId":"OG001","value":"-15.3","spread":"11.10"},{"groupId":"OG002","value":"-16.4","spread":"10.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.78","spread":"2.645"},{"groupId":"OG001","value":"-3.20","spread":"2.557"},{"groupId":"OG002","value":"-2.92","spread":"2.686"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.10","spread":"2.707"},{"groupId":"OG001","value":"-3.62","spread":"2.530"},{"groupId":"OG002","value":"-3.46","spread":"2.574"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.18","spread":"2.724"},{"groupId":"OG001","value":"-3.57","spread":"2.566"},{"groupId":"OG002","value":"-3.38","spread":"2.620"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.35","spread":"2.595"},{"groupId":"OG001","value":"-3.64","spread":"2.568"},{"groupId":"OG002","value":"-3.42","spread":"2.669"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.41","spread":"2.578"},{"groupId":"OG001","value":"-3.69","spread":"2.625"},{"groupId":"OG002","value":"-3.52","spread":"2.615"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.87","spread":"2.761"},{"groupId":"OG001","value":"-3.29","spread":"2.553"},{"groupId":"OG002","value":"-3.09","spread":"2.523"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.08","spread":"2.786"},{"groupId":"OG001","value":"-3.58","spread":"2.446"},{"groupId":"OG002","value":"-3.49","spread":"2.500"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.32","spread":"2.860"},{"groupId":"OG001","value":"-3.63","spread":"2.512"},{"groupId":"OG002","value":"-3.38","spread":"2.501"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.46","spread":"2.752"},{"groupId":"OG001","value":"-3.67","spread":"2.572"},{"groupId":"OG002","value":"-3.50","spread":"2.579"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.40","spread":"2.846"},{"groupId":"OG001","value":"-3.67","spread":"2.612"},{"groupId":"OG002","value":"-3.73","spread":"2.493"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.79","spread":"1.992"},{"groupId":"OG001","value":"-4.77","spread":"2.001"},{"groupId":"OG002","value":"-4.82","spread":"2.117"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.06","spread":"2.037"},{"groupId":"OG001","value":"-4.98","spread":"1.992"},{"groupId":"OG002","value":"-5.01","spread":"2.105"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.23","spread":"1.995"},{"groupId":"OG001","value":"-4.86","spread":"2.044"},{"groupId":"OG002","value":"-5.03","spread":"2.078"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"2.040"},{"groupId":"OG001","value":"-5.06","spread":"2.074"},{"groupId":"OG002","value":"-5.09","spread":"2.142"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.26","spread":"2.098"},{"groupId":"OG001","value":"-5.05","spread":"2.011"},{"groupId":"OG002","value":"-5.18","spread":"2.044"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3899","spread":"0.58250"},{"groupId":"OG001","value":"-0.4801","spread":"0.56246"},{"groupId":"OG002","value":"-0.5111","spread":"0.58347"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4668","spread":"0.59226"},{"groupId":"OG001","value":"-0.5120","spread":"0.54928"},{"groupId":"OG002","value":"-0.5631","spread":"0.54528"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4740","spread":"0.57852"},{"groupId":"OG001","value":"-0.5694","spread":"0.56421"},{"groupId":"OG002","value":"-0.5448","spread":"0.54739"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5041","spread":"0.59716"},{"groupId":"OG001","value":"-0.5653","spread":"0.59488"},{"groupId":"OG002","value":"-0.5656","spread":"0.57921"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5356","spread":"0.56707"},{"groupId":"OG001","value":"-0.5859","spread":"0.58199"},{"groupId":"OG002","value":"-0.6000","spread":"0.56858"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.262","spread":"2.8315"},{"groupId":"OG001","value":"-1.021","spread":"2.2301"},{"groupId":"OG002","value":"-0.959","spread":"2.4188"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.212","spread":"2.3061"},{"groupId":"OG001","value":"-1.081","spread":"2.1585"},{"groupId":"OG002","value":"-1.060","spread":"2.3334"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.283","spread":"2.8163"},{"groupId":"OG001","value":"-1.098","spread":"2.3654"},{"groupId":"OG002","value":"-1.017","spread":"2.2801"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.230","spread":"2.4262"},{"groupId":"OG001","value":"-1.101","spread":"2.1216"},{"groupId":"OG002","value":"-0.940","spread":"2.3781"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.244","spread":"2.5828"},{"groupId":"OG001","value":"-1.129","spread":"2.2261"},{"groupId":"OG002","value":"-1.042","spread":"2.0600"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100","description":"ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.64","spread":"30.161"},{"groupId":"OG001","value":"-83.03","spread":"30.210"},{"groupId":"OG002","value":"-84.27","spread":"23.698"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.41","spread":"24.049"},{"groupId":"OG001","value":"-86.08","spread":"29.764"},{"groupId":"OG002","value":"-86.41","spread":"22.642"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.98","spread":"20.617"},{"groupId":"OG001","value":"-86.05","spread":"21.096"},{"groupId":"OG002","value":"-85.82","spread":"22.291"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.72","spread":"22.243"},{"groupId":"OG001","value":"-87.68","spread":"23.304"},{"groupId":"OG002","value":"-87.16","spread":"24.888"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.61","spread":"21.214"},{"groupId":"OG001","value":"-86.19","spread":"40.865"},{"groupId":"OG002","value":"-86.31","spread":"24.106"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.29","spread":"35.725"},{"groupId":"OG001","value":"-70.18","spread":"32.062"},{"groupId":"OG002","value":"-70.54","spread":"31.311"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-74.28","spread":"29.764"},{"groupId":"OG001","value":"-75.63","spread":"29.437"},{"groupId":"OG002","value":"-74.40","spread":"29.760"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-75.71","spread":"27.653"},{"groupId":"OG001","value":"-74.71","spread":"29.728"},{"groupId":"OG002","value":"-75.11","spread":"28.559"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-77.21","spread":"27.045"},{"groupId":"OG001","value":"-78.01","spread":"26.112"},{"groupId":"OG002","value":"-75.45","spread":"32.489"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-77.04","spread":"27.510"},{"groupId":"OG001","value":"-75.96","spread":"32.600"},{"groupId":"OG002","value":"-76.21","spread":"27.345"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.52","spread":"44.939"},{"groupId":"OG001","value":"-48.81","spread":"39.191"},{"groupId":"OG002","value":"-43.86","spread":"45.891"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.91","spread":"44.371"},{"groupId":"OG001","value":"-55.77","spread":"38.780"},{"groupId":"OG002","value":"-52.43","spread":"41.186"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.02","spread":"44.989"},{"groupId":"OG001","value":"-54.38","spread":"39.135"},{"groupId":"OG002","value":"-51.34","spread":"41.903"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.64","spread":"40.991"},{"groupId":"OG001","value":"-55.28","spread":"40.388"},{"groupId":"OG002","value":"-52.59","spread":"43.131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.82","spread":"42.970"},{"groupId":"OG001","value":"-56.36","spread":"41.310"},{"groupId":"OG002","value":"-54.27","spread":"40.819"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.70","spread":"44.981"},{"groupId":"OG001","value":"-48.48","spread":"38.982"},{"groupId":"OG002","value":"-46.07","spread":"40.614"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.93","spread":"44.220"},{"groupId":"OG001","value":"-53.84","spread":"35.096"},{"groupId":"OG002","value":"-52.47","spread":"38.155"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.42","spread":"45.106"},{"groupId":"OG001","value":"-54.41","spread":"35.276"},{"groupId":"OG002","value":"-50.66","spread":"40.992"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.38","spread":"42.315"},{"groupId":"OG001","value":"-54.17","spread":"37.132"},{"groupId":"OG002","value":"-51.86","spread":"44.532"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.17","spread":"44.804"},{"groupId":"OG001","value":"-55.08","spread":"37.052"},{"groupId":"OG002","value":"-57.09","spread":"34.970"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.24","spread":"24.771"},{"groupId":"OG001","value":"-72.95","spread":"24.168"},{"groupId":"OG002","value":"-72.58","spread":"24.579"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-74.76","spread":"23.290"},{"groupId":"OG001","value":"-76.00","spread":"22.550"},{"groupId":"OG002","value":"-74.48","spread":"26.280"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-77.68","spread":"23.015"},{"groupId":"OG001","value":"-74.42","spread":"25.014"},{"groupId":"OG002","value":"-75.56","spread":"23.613"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-75.77","spread":"23.674"},{"groupId":"OG001","value":"-76.77","spread":"24.433"},{"groupId":"OG002","value":"-76.49","spread":"24.355"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-78.11","spread":"24.049"},{"groupId":"OG001","value":"-77.15","spread":"23.217"},{"groupId":"OG002","value":"-77.82","spread":"22.733"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.27","spread":"54.587"},{"groupId":"OG001","value":"-33.28","spread":"64.067"},{"groupId":"OG002","value":"-35.17","spread":"66.105"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.34","spread":"49.027"},{"groupId":"OG001","value":"-37.47","spread":"57.370"},{"groupId":"OG002","value":"-44.33","spread":"44.064"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.38","spread":"47.311"},{"groupId":"OG001","value":"-40.08","spread":"58.932"},{"groupId":"OG002","value":"-41.84","spread":"47.877"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.73","spread":"47.541"},{"groupId":"OG001","value":"-40.10","spread":"58.703"},{"groupId":"OG002","value":"-43.18","spread":"52.116"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.36","spread":"44.407"},{"groupId":"OG001","value":"-42.84","spread":"54.187"},{"groupId":"OG002","value":"-47.54","spread":"47.265"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.67","spread":"205.761"},{"groupId":"OG001","value":"-23.41","spread":"104.622"},{"groupId":"OG002","value":"-1.34","spread":"194.673"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"330.574"},{"groupId":"OG001","value":"-28.38","spread":"138.159"},{"groupId":"OG002","value":"-13.91","spread":"174.522"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.76","spread":"226.332"},{"groupId":"OG001","value":"7.85","spread":"502.170"},{"groupId":"OG002","value":"-24.22","spread":"110.486"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"387.986"},{"groupId":"OG001","value":"-26.87","spread":"114.471"},{"groupId":"OG002","value":"-19.89","spread":"131.695"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.33","spread":"196.246"},{"groupId":"OG001","value":"-23.99","spread":"150.816"},{"groupId":"OG002","value":"-14.35","spread":"171.666"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52","description":"ACR 20 response was defined as \\>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"90.4","spread":null},{"groupId":"OG002","value":"93.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52","description":"ACR 50 response was defined as \\>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.3","spread":null},{"groupId":"OG001","value":"81.9","spread":null},{"groupId":"OG002","value":"83.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52","description":"ACR 70 response was defined as \\>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \\>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \\[mm\\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1","spread":null},{"groupId":"OG001","value":"80.9","spread":null},{"groupId":"OG002","value":"71.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100","description":"HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3899","spread":"0.58250"},{"groupId":"OG001","value":"-0.4801","spread":"0.56246"},{"groupId":"OG002","value":"-0.5111","spread":"0.58347"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4668","spread":"0.59226"},{"groupId":"OG001","value":"-0.5120","spread":"0.54928"},{"groupId":"OG002","value":"-0.5631","spread":"0.54528"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4740","spread":"0.57852"},{"groupId":"OG001","value":"-0.5694","spread":"0.56421"},{"groupId":"OG002","value":"-0.5448","spread":"0.54739"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5041","spread":"0.59716"},{"groupId":"OG001","value":"-0.5653","spread":"0.59488"},{"groupId":"OG002","value":"-0.5656","spread":"0.57921"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5356","spread":"0.56707"},{"groupId":"OG001","value":"-0.5859","spread":"0.58199"},{"groupId":"OG002","value":"-0.6000","spread":"0.56858"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline","description":"HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"60.6","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.2","spread":null},{"groupId":"OG001","value":"64.9","spread":null},{"groupId":"OG002","value":"69.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null},{"groupId":"OG001","value":"68.4","spread":null},{"groupId":"OG002","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.9","spread":null},{"groupId":"OG001","value":"66.8","spread":null},{"groupId":"OG002","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null},{"groupId":"OG001","value":"70.7","spread":null},{"groupId":"OG002","value":"70.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52","description":"HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null},{"groupId":"OG001","value":"90.4","spread":null},{"groupId":"OG002","value":"88.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100","description":"DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \\<=3.2 at visit and \\>1.2 improvement; Moderate response: \\>3.2 at visit and \\>1.2 improvement or \\<=5.1 at visit and \\>0.6-1.2 improvement; No response: \\<=0.6 improvement, or \\>5.1 at visit and \\<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":null},{"groupId":"OG001","value":"89.7","spread":null},{"groupId":"OG002","value":"90.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"92.5","spread":null},{"groupId":"OG002","value":"92.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null},{"groupId":"OG001","value":"90.2","spread":null},{"groupId":"OG002","value":"93.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","spread":null},{"groupId":"OG001","value":"92.7","spread":null},{"groupId":"OG002","value":"92.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","spread":null},{"groupId":"OG001","value":"90.6","spread":null},{"groupId":"OG002","value":"92.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100","description":"DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \\<2.6 at the analysis visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"39.7","spread":null},{"groupId":"OG002","value":"40.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null},{"groupId":"OG001","value":"44.9","spread":null},{"groupId":"OG002","value":"49.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null},{"groupId":"OG001","value":"44.2","spread":null},{"groupId":"OG002","value":"43.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.8","spread":null},{"groupId":"OG001","value":"50.9","spread":null},{"groupId":"OG002","value":"48.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4","spread":null},{"groupId":"OG001","value":"47.5","spread":null},{"groupId":"OG002","value":"51.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100","description":"DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.14","spread":"1.142"},{"groupId":"OG001","value":"-2.08","spread":"1.124"},{"groupId":"OG002","value":"-2.14","spread":"1.118"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.29","spread":"1.132"},{"groupId":"OG001","value":"-2.25","spread":"1.170"},{"groupId":"OG002","value":"-2.30","spread":"1.143"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.35","spread":"1.110"},{"groupId":"OG001","value":"-2.24","spread":"1.147"},{"groupId":"OG002","value":"-2.24","spread":"1.087"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.40","spread":"1.087"},{"groupId":"OG001","value":"-2.35","spread":"1.181"},{"groupId":"OG002","value":"-2.31","spread":"1.156"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.42","spread":"1.144"},{"groupId":"OG001","value":"-2.37","spread":"1.215"},{"groupId":"OG002","value":"-2.36","spread":"1.120"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100","description":"The modified PsARC response was defined as improvement in at least 2 of the four criteria: \\>=30% decrease in swollen joint count, \\>=30% decrease in tender joint count, \\>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \\>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.4","spread":null},{"groupId":"OG001","value":"86.2","spread":null},{"groupId":"OG002","value":"83.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"89.9","spread":null},{"groupId":"OG002","value":"87.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":null},{"groupId":"OG001","value":"88.8","spread":null},{"groupId":"OG002","value":"90.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.4","spread":null},{"groupId":"OG001","value":"87.7","spread":null},{"groupId":"OG002","value":"87.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null},{"groupId":"OG001","value":"89.3","spread":null},{"groupId":"OG002","value":"88.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline","description":"Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\\>0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.3","spread":null},{"groupId":"OG001","value":"66.0","spread":null},{"groupId":"OG002","value":"61.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":null},{"groupId":"OG001","value":"71.8","spread":null},{"groupId":"OG002","value":"67.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":null},{"groupId":"OG001","value":"77.5","spread":null},{"groupId":"OG002","value":"67.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline","description":"Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.59"},{"groupId":"OG001","value":"-1.9","spread":"1.66"},{"groupId":"OG002","value":"-2.1","spread":"1.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.52"},{"groupId":"OG001","value":"-2.1","spread":"1.66"},{"groupId":"OG002","value":"-2.2","spread":"1.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"1.70"},{"groupId":"OG001","value":"-2.1","spread":"1.65"},{"groupId":"OG002","value":"-2.2","spread":"1.80"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline","description":"The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \\>0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null},{"groupId":"OG001","value":"81.7","spread":null},{"groupId":"OG002","value":"80.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.2","spread":null},{"groupId":"OG001","value":"84.0","spread":null},{"groupId":"OG002","value":"82.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.7","spread":null},{"groupId":"OG001","value":"91.1","spread":null},{"groupId":"OG002","value":"82.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline","description":"The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"9.22"},{"groupId":"OG001","value":"-7.3","spread":"9.78"},{"groupId":"OG002","value":"-7.4","spread":"8.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","spread":"9.55"},{"groupId":"OG001","value":"-7.8","spread":"10.24"},{"groupId":"OG002","value":"-7.6","spread":"8.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.1","spread":"9.63"},{"groupId":"OG001","value":"-7.9","spread":"10.12"},{"groupId":"OG002","value":"-7.9","spread":"9.14"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PASDAS Score at Weeks 52, 76 and 100","description":"PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \\[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \\[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \\[where 0= no tenderness and 3= extreme tenderness\\] and recoding to 0-1, where any score \\> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.054","spread":"1.4954"},{"groupId":"OG001","value":"-3.189","spread":"1.5216"},{"groupId":"OG002","value":"-3.184","spread":"1.4576"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.503","spread":"1.4708"},{"groupId":"OG001","value":"-3.418","spread":"1.5646"},{"groupId":"OG002","value":"-3.436","spread":"1.4428"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.574","spread":"1.4785"},{"groupId":"OG001","value":"-3.586","spread":"1.5425"},{"groupId":"OG002","value":"-3.549","spread":"1.4635"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100","description":"PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining PtGA of Disease Activity (arthritis and psoriasis, using VAS \\[0-100 mm, 0=excellent and 100= poor), PGA of Disease Activity (using VAS \\[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \\[where 0= no tenderness and 3= extreme tenderness\\] and recoding to 0-1, where any score \\> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity. Low: PASDAS \\<= 3.2; Very low: PASDAS \\<= 1.9.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null},{"groupId":"OG001","value":"44.8","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"22.0","spread":null},{"groupId":"OG002","value":"16.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.1","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"49.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null},{"groupId":"OG001","value":"23.4","spread":null},{"groupId":"OG002","value":"22.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":null},{"groupId":"OG001","value":"54.7","spread":null},{"groupId":"OG002","value":"57.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":null},{"groupId":"OG001","value":"26.0","spread":null},{"groupId":"OG002","value":"23.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100","description":"GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \\[2.367\\*HAQ-DI\\]-\\[0.234\\*SF-PCS\\]-\\[0.244\\*SF-MCS\\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.105","spread":"1.6208"},{"groupId":"OG001","value":"-3.266","spread":"1.6443"},{"groupId":"OG002","value":"-3.298","spread":"1.5457"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.499","spread":"1.6303"},{"groupId":"OG001","value":"-3.528","spread":"1.5778"},{"groupId":"OG002","value":"-3.541","spread":"1.5048"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.561","spread":"1.6389"},{"groupId":"OG001","value":"-3.656","spread":"1.6071"},{"groupId":"OG002","value":"-3.664","spread":"1.5205"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100","description":"GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \\[2.367\\*HAQ-DI\\]-\\[0.234\\*SF-PCS\\]-\\[0.244\\*SF-MCS\\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \\<=2.3 at the analysis visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"42.7","spread":null},{"groupId":"OG002","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null},{"groupId":"OG001","value":"48.9","spread":null},{"groupId":"OG002","value":"49.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"51.1","spread":null},{"groupId":"OG002","value":"54.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100","description":"DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \\<lower limit of quantification \\[LLOQ\\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.274","spread":"18.8900"},{"groupId":"OG001","value":"-30.604","spread":"17.5366"},{"groupId":"OG002","value":"-32.563","spread":"16.4765"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.918","spread":"18.0463"},{"groupId":"OG001","value":"-33.146","spread":"18.1727"},{"groupId":"OG002","value":"-34.900","spread":"17.5749"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.391","spread":"17.4074"},{"groupId":"OG001","value":"-33.062","spread":"17.5186"},{"groupId":"OG002","value":"-34.590","spread":"16.5401"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.240","spread":"17.7891"},{"groupId":"OG001","value":"-33.622","spread":"18.0612"},{"groupId":"OG002","value":"-34.570","spread":"18.2685"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.819","spread":"17.9807"},{"groupId":"OG001","value":"-34.019","spread":"19.2678"},{"groupId":"OG002","value":"-35.549","spread":"16.5533"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100","description":"DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound. Low: DAPSA\\<=14; Remission: DAPSA\\<=4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.7","spread":null},{"groupId":"OG001","value":"55.2","spread":null},{"groupId":"OG002","value":"55.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"19.4","spread":null},{"groupId":"OG002","value":"17.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null},{"groupId":"OG001","value":"64.3","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"23.8","spread":null},{"groupId":"OG002","value":"23.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":null},{"groupId":"OG001","value":"61.2","spread":null},{"groupId":"OG002","value":"61.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":null},{"groupId":"OG001","value":"26.8","spread":null},{"groupId":"OG002","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":null},{"groupId":"OG001","value":"66.5","spread":null},{"groupId":"OG002","value":"64.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"28.0","spread":null},{"groupId":"OG002","value":"23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.9","spread":null},{"groupId":"OG001","value":"65.9","spread":null},{"groupId":"OG002","value":"68.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"26.9","spread":null},{"groupId":"OG002","value":"23.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100","description":"The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.78","spread":"2.392"},{"groupId":"OG001","value":"-3.83","spread":"2.458"},{"groupId":"OG002","value":"-4.14","spread":"2.358"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.39","spread":"2.425"},{"groupId":"OG001","value":"-4.16","spread":"2.539"},{"groupId":"OG002","value":"-4.47","spread":"2.347"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.44","spread":"2.484"},{"groupId":"OG001","value":"-4.38","spread":"2.433"},{"groupId":"OG002","value":"-4.52","spread":"2.519"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100","description":"The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \\<=3.2 at the analysis visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.6","spread":null},{"groupId":"OG001","value":"61.2","spread":null},{"groupId":"OG002","value":"60.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"63.7","spread":null},{"groupId":"OG002","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":null},{"groupId":"OG001","value":"71.7","spread":null},{"groupId":"OG002","value":"68.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100","description":"MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\\<=1, Swollen joint count (66 joints) \\<=1, Psoriasis activity and severity index \\<=1, Patient's Assessment of Pain \\<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \\<=20 on a 100-unit VAS, HAQ-DI score \\<=0.5, and Tender entheseal points \\<= 1 (LEI index score \\<= 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":null},{"groupId":"OG001","value":"32.8","spread":null},{"groupId":"OG002","value":"37.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"39.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5","spread":null},{"groupId":"OG001","value":"44.6","spread":null},{"groupId":"OG002","value":"42.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With VLDA at Weeks 52, 76 and 100","description":"A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \\<=1; swollen joint count \\<=1; PASI \\<=1; patient pain VAS score of \\<=15; patient global disease activity VAS \\[arthritis and psoriasis\\] score of \\<=20; Health Assessment Questionnaire (HAQ) score \\<=0.5; and tender entheseal points \\<=1) at that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"16.8","spread":null},{"groupId":"OG002","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":null},{"groupId":"OG001","value":"19.6","spread":null},{"groupId":"OG002","value":"14.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"18.8","spread":null},{"groupId":"OG002","value":"15.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline","description":"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.986","spread":"2.4945"},{"groupId":"OG001","value":"-2.923","spread":"2.5194"},{"groupId":"OG002","value":"-3.084","spread":"2.1843"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.311","spread":"2.6106"},{"groupId":"OG001","value":"-3.377","spread":"2.5969"},{"groupId":"OG002","value":"-3.129","spread":"2.1122"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.718","spread":"2.3960"},{"groupId":"OG001","value":"-3.472","spread":"2.5233"},{"groupId":"OG002","value":"-3.330","spread":"2.1598"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline","description":"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":null},{"groupId":"OG001","value":"69.8","spread":null},{"groupId":"OG002","value":"79.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1","spread":null},{"groupId":"OG001","value":"82.0","spread":null},{"groupId":"OG002","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.8","spread":null},{"groupId":"OG001","value":"77.0","spread":null},{"groupId":"OG002","value":"82.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"42.9","spread":null},{"groupId":"OG002","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null},{"groupId":"OG001","value":"52.5","spread":null},{"groupId":"OG002","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":null},{"groupId":"OG001","value":"57.4","spread":null},{"groupId":"OG002","value":"55.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"27.0","spread":null},{"groupId":"OG002","value":"30.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"31.1","spread":null},{"groupId":"OG002","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"39.3","spread":null},{"groupId":"OG002","value":"32.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"11.1","spread":null},{"groupId":"OG002","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"13.1","spread":null},{"groupId":"OG002","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null},{"groupId":"OG001","value":"11.5","spread":null},{"groupId":"OG002","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.030","spread":"10.0077"},{"groupId":"OG001","value":"-11.991","spread":"12.1194"},{"groupId":"OG002","value":"-12.875","spread":"11.2905"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.313","spread":"10.0631"},{"groupId":"OG001","value":"-11.991","spread":"12.2656"},{"groupId":"OG002","value":"-13.242","spread":"11.8845"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.089","spread":"10.0239"},{"groupId":"OG001","value":"-12.101","spread":"12.1322"},{"groupId":"OG002","value":"-13.274","spread":"11.9673"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \\>=50% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null},{"groupId":"OG001","value":"97.0","spread":null},{"groupId":"OG002","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null},{"groupId":"OG001","value":"97.0","spread":null},{"groupId":"OG002","value":"98.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \\>=75% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"88.8","spread":null},{"groupId":"OG002","value":"91.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null},{"groupId":"OG001","value":"87.9","spread":null},{"groupId":"OG002","value":"93.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.9","spread":null},{"groupId":"OG001","value":"87.8","spread":null},{"groupId":"OG002","value":"89.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \\>=90% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"76.9","spread":null},{"groupId":"OG002","value":"81.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"75.8","spread":null},{"groupId":"OG002","value":"80.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1","spread":null},{"groupId":"OG001","value":"59.4","spread":null},{"groupId":"OG002","value":"68.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","spread":null},{"groupId":"OG001","value":"57.3","spread":null},{"groupId":"OG002","value":"64.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \\>=75% improvement in PASI score from baseline. ACR 20: \\>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \\>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"73.4","spread":null},{"groupId":"OG002","value":"70.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"75.8","spread":null},{"groupId":"OG002","value":"76.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null},{"groupId":"OG001","value":"76.1","spread":null},{"groupId":"OG002","value":"77.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \\>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \\>=30% decrease in SJC and TJC, \\>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \\>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null},{"groupId":"OG001","value":"79.3","spread":null},{"groupId":"OG002","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null},{"groupId":"OG001","value":"79.4","spread":null},{"groupId":"OG002","value":"82.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":null},{"groupId":"OG001","value":"81.1","spread":null},{"groupId":"OG002","value":"78.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \\>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). IGA Response is defined as achieving IGA score of 0 or 1, and \\>=2 grade reduction from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","spread":null},{"groupId":"OG001","value":"76.9","spread":null},{"groupId":"OG002","value":"84.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"77.6","spread":null},{"groupId":"OG002","value":"86.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.1","spread":null},{"groupId":"OG001","value":"76.4","spread":null},{"groupId":"OG002","value":"82.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \\>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"59.8","spread":null},{"groupId":"OG002","value":"65.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"64.2","spread":null},{"groupId":"OG002","value":"72.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null},{"groupId":"OG001","value":"58.8","spread":null},{"groupId":"OG002","value":"67.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"68.4","spread":null},{"groupId":"OG002","value":"68.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.9","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"68.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":null},{"groupId":"OG001","value":"69.6","spread":null},{"groupId":"OG002","value":"64.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":null},{"groupId":"OG001","value":"92.2","spread":null},{"groupId":"OG002","value":"89.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.9","spread":null},{"groupId":"OG001","value":"89.0","spread":null},{"groupId":"OG002","value":"90.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"94.4","spread":null},{"groupId":"OG002","value":"88.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline","description":"Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.855","spread":"7.2738"},{"groupId":"OG001","value":"-9.272","spread":"7.3903"},{"groupId":"OG002","value":"-9.873","spread":"6.8832"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.090","spread":"7.0888"},{"groupId":"OG001","value":"-9.180","spread":"7.2977"},{"groupId":"OG002","value":"-9.610","spread":"7.0383"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.130","spread":"7.2798"},{"groupId":"OG001","value":"-9.291","spread":"7.2851"},{"groupId":"OG002","value":"-9.635","spread":"7.0884"}]}]}]},{"type":"SECONDARY","title":"Change in Modified vdH-S Score From Baseline to Week 100","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":"6.859"},{"groupId":"OG001","value":"1.50","spread":"4.393"},{"groupId":"OG002","value":"1.68","spread":"7.018"}]}]}]},{"type":"SECONDARY","title":"Change in Total Modified vdH-S Score From Week 52 to Week 100","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"3.742"},{"groupId":"OG001","value":"0.46","spread":"2.419"},{"groupId":"OG002","value":"0.75","spread":"4.021"}]}]}]},{"type":"SECONDARY","title":"Change in Modified vdH-s Erosion Score From Baseline to Week 100","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"4.034"},{"groupId":"OG001","value":"1.01","spread":"3.355"},{"groupId":"OG002","value":"1.02","spread":"4.676"}]}]}]},{"type":"SECONDARY","title":"Change in Modified vdH-s Erosion Score From Week 52 to Week 100","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"1.978"},{"groupId":"OG001","value":"0.26","spread":"1.751"},{"groupId":"OG002","value":"0.45","spread":"2.900"}]}]}]},{"type":"SECONDARY","title":"Change in Modified vdH-s JSN Score From Baseline to Week 100","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"2.984"},{"groupId":"OG001","value":"0.50","spread":"1.387"},{"groupId":"OG002","value":"0.66","spread":"2.722"}]}]}]},{"type":"SECONDARY","title":"Change in Modified vdH-s JSN Score From Week 52 to Week 100","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"1.904"},{"groupId":"OG001","value":"0.20","spread":"0.917"},{"groupId":"OG002","value":"0.30","spread":"1.319"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"2.917"},{"groupId":"OG001","value":"0.67","spread":"2.807"},{"groupId":"OG002","value":"0.49","spread":"3.007"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"2.443"},{"groupId":"OG001","value":"0.34","spread":"1.247"},{"groupId":"OG002","value":"0.32","spread":"1.845"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"5.244"},{"groupId":"OG001","value":"1.02","spread":"3.815"},{"groupId":"OG002","value":"0.81","spread":"4.532"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"1.596"},{"groupId":"OG001","value":"0.33","spread":"1.362"},{"groupId":"OG002","value":"0.53","spread":"2.436"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.912"},{"groupId":"OG001","value":"0.15","spread":"0.652"},{"groupId":"OG002","value":"0.34","spread":"1.608"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"2.373"},{"groupId":"OG001","value":"0.48","spread":"1.652"},{"groupId":"OG002","value":"0.87","spread":"3.761"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"62.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"63.9","spread":null},{"groupId":"OG002","value":"72.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null},{"groupId":"OG001","value":"61.1","spread":null},{"groupId":"OG002","value":"65.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"73.1","spread":null},{"groupId":"OG002","value":"75.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null},{"groupId":"OG001","value":"68.5","spread":null},{"groupId":"OG002","value":"73.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"79.6","spread":null},{"groupId":"OG002","value":"81.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100","description":"Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \\<=SDC of 3.46.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8","spread":null},{"groupId":"OG001","value":"84.7","spread":null},{"groupId":"OG002","value":"87.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100","description":"Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic erosion progression was defined as change from baseline in the modified vdH-S erosion score \\<=SDC of 2.66.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8","spread":null},{"groupId":"OG001","value":"87.0","spread":null},{"groupId":"OG002","value":"88.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100","description":"Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \\<=SDC of 1.66.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"89.4","spread":null},{"groupId":"OG002","value":"88.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100","description":"Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"4.4","spread":null},{"groupId":"OG002","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"4.6","spread":null},{"groupId":"OG002","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.170","spread":"8.2195"},{"groupId":"OG001","value":"9.438","spread":"8.2854"},{"groupId":"OG002","value":"9.023","spread":"8.6263"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.762","spread":"8.5908"},{"groupId":"OG001","value":"10.814","spread":"9.0290"},{"groupId":"OG002","value":"9.707","spread":"8.5010"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.508","spread":"8.6819"},{"groupId":"OG001","value":"11.282","spread":"9.2753"},{"groupId":"OG002","value":"10.559","spread":"8.7449"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.383","spread":"10.9402"},{"groupId":"OG001","value":"4.540","spread":"9.7848"},{"groupId":"OG002","value":"4.127","spread":"9.1368"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.838","spread":"11.0526"},{"groupId":"OG001","value":"5.034","spread":"10.0334"},{"groupId":"OG002","value":"5.194","spread":"9.4899"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.610","spread":"11.2527"},{"groupId":"OG001","value":"4.718","spread":"9.9014"},{"groupId":"OG002","value":"4.936","spread":"9.5935"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.757","spread":"8.9727"},{"groupId":"OG001","value":"8.406","spread":"8.8407"},{"groupId":"OG002","value":"8.493","spread":"8.7691"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.824","spread":"9.6648"},{"groupId":"OG001","value":"9.807","spread":"9.5044"},{"groupId":"OG002","value":"9.294","spread":"8.2020"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.738","spread":"9.8405"},{"groupId":"OG001","value":"10.953","spread":"9.7761"},{"groupId":"OG002","value":"10.126","spread":"8.9271"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.538","spread":"8.5151"},{"groupId":"OG001","value":"7.665","spread":"8.2925"},{"groupId":"OG002","value":"7.372","spread":"7.7581"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.372","spread":"8.7202"},{"groupId":"OG001","value":"9.171","spread":"8.5844"},{"groupId":"OG002","value":"8.579","spread":"7.6709"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.181","spread":"8.6596"},{"groupId":"OG001","value":"9.342","spread":"9.1746"},{"groupId":"OG002","value":"8.921","spread":"8.1775"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.536","spread":"8.4602"},{"groupId":"OG001","value":"10.201","spread":"8.7312"},{"groupId":"OG002","value":"9.525","spread":"9.8357"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.368","spread":"9.1058"},{"groupId":"OG001","value":"11.552","spread":"9.8591"},{"groupId":"OG002","value":"10.300","spread":"9.0504"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.696","spread":"9.3854"},{"groupId":"OG001","value":"11.585","spread":"10.3527"},{"groupId":"OG002","value":"10.998","spread":"8.9230"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.533","spread":"8.5245"},{"groupId":"OG001","value":"7.097","spread":"7.2500"},{"groupId":"OG002","value":"6.450","spread":"8.4316"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.203","spread":"8.3372"},{"groupId":"OG001","value":"7.470","spread":"7.6119"},{"groupId":"OG002","value":"6.761","spread":"7.9631"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.710","spread":"8.7265"},{"groupId":"OG001","value":"7.066","spread":"7.5829"},{"groupId":"OG002","value":"7.132","spread":"8.4887"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.997","spread":"9.3878"},{"groupId":"OG001","value":"8.695","spread":"9.5033"},{"groupId":"OG002","value":"7.637","spread":"9.4393"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.859","spread":"9.4372"},{"groupId":"OG001","value":"9.388","spread":"9.8618"},{"groupId":"OG002","value":"8.659","spread":"9.6026"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.648","spread":"9.4778"},{"groupId":"OG001","value":"9.827","spread":"9.9348"},{"groupId":"OG002","value":"9.155","spread":"9.3569"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.361","spread":"10.9927"},{"groupId":"OG001","value":"7.304","spread":"10.1003"},{"groupId":"OG002","value":"6.810","spread":"9.5118"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.509","spread":"10.4249"},{"groupId":"OG001","value":"8.623","spread":"9.5176"},{"groupId":"OG002","value":"7.914","spread":"9.5191"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.825","spread":"10.8558"},{"groupId":"OG001","value":"8.080","spread":"9.5383"},{"groupId":"OG002","value":"8.113","spread":"9.4847"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.111","spread":"10.9413"},{"groupId":"OG001","value":"4.998","spread":"10.1964"},{"groupId":"OG002","value":"4.699","spread":"8.7759"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.199","spread":"11.1875"},{"groupId":"OG001","value":"5.757","spread":"10.0737"},{"groupId":"OG002","value":"5.433","spread":"9.2389"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.784","spread":"11.9482"},{"groupId":"OG001","value":"5.720","spread":"10.1991"},{"groupId":"OG002","value":"5.128","spread":"9.7998"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.209","spread":"10.0958"},{"groupId":"OG001","value":"4.826","spread":"9.4038"},{"groupId":"OG002","value":"4.839","spread":"9.4029"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.481","spread":"10.5927"},{"groupId":"OG001","value":"5.430","spread":"10.0802"},{"groupId":"OG002","value":"6.124","spread":"8.7930"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.514","spread":"10.6204"},{"groupId":"OG001","value":"5.477","spread":"10.1202"},{"groupId":"OG002","value":"6.148","spread":"8.8743"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.4","spread":null},{"groupId":"OG001","value":"66.8","spread":null},{"groupId":"OG002","value":"65.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"73.8","spread":null},{"groupId":"OG002","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"70.1","spread":null},{"groupId":"OG002","value":"68.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100","description":"SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","spread":null},{"groupId":"OG001","value":"45.3","spread":null},{"groupId":"OG002","value":"38.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"44.4","spread":null},{"groupId":"OG002","value":"43.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null},{"groupId":"OG001","value":"46.4","spread":null},{"groupId":"OG002","value":"43.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100","description":"The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \\[4 - score\\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.692","spread":"9.3071"},{"groupId":"OG001","value":"8.935","spread":"9.5033"},{"groupId":"OG002","value":"7.699","spread":"9.1417"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.167","spread":"9.0455"},{"groupId":"OG001","value":"9.596","spread":"10.4788"},{"groupId":"OG002","value":"8.632","spread":"8.8429"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.435","spread":"9.4513"},{"groupId":"OG001","value":"10.107","spread":"10.2076"},{"groupId":"OG002","value":"9.127","spread":"8.9948"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100","description":"The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \\[4 - score\\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.7","spread":null},{"groupId":"OG001","value":"69.4","spread":null},{"groupId":"OG002","value":"68.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"69.3","spread":null},{"groupId":"OG002","value":"74.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null},{"groupId":"OG001","value":"72.8","spread":null},{"groupId":"OG002","value":"74.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS","description":"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.608","spread":"25.5992"},{"groupId":"OG001","value":"23.392","spread":"23.6990"},{"groupId":"OG002","value":"20.190","spread":"24.8348"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.176","spread":"27.7205"},{"groupId":"OG001","value":"25.053","spread":"26.0372"},{"groupId":"OG002","value":"22.251","spread":"24.6934"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.901","spread":"28.4028"},{"groupId":"OG001","value":"27.152","spread":"26.5221"},{"groupId":"OG002","value":"25.909","spread":"26.0995"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index","description":"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health \"today\". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.138","spread":"0.1608"},{"groupId":"OG001","value":"0.150","spread":"0.1445"},{"groupId":"OG002","value":"0.138","spread":"0.1458"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.154","spread":"0.1744"},{"groupId":"OG001","value":"0.169","spread":"0.1564"},{"groupId":"OG002","value":"0.147","spread":"0.1471"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.164","spread":"0.1605"},{"groupId":"OG001","value":"0.164","spread":"0.1596"},{"groupId":"OG002","value":"0.156","spread":"0.1543"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.45","spread":"25.544"},{"groupId":"OG001","value":"-4.50","spread":"20.530"},{"groupId":"OG002","value":"-1.83","spread":"17.191"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.92","spread":"26.032"},{"groupId":"OG001","value":"-6.22","spread":"23.133"},{"groupId":"OG002","value":"-2.39","spread":"19.277"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.81","spread":"24.313"},{"groupId":"OG001","value":"-5.81","spread":"21.606"},{"groupId":"OG002","value":"-1.56","spread":"16.956"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.81","spread":"31.391"},{"groupId":"OG001","value":"-27.93","spread":"25.263"},{"groupId":"OG002","value":"-22.62","spread":"26.058"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.90","spread":"28.965"},{"groupId":"OG001","value":"-29.91","spread":"24.549"},{"groupId":"OG002","value":"-26.13","spread":"25.412"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.73","spread":"30.933"},{"groupId":"OG001","value":"-30.65","spread":"24.771"},{"groupId":"OG002","value":"-27.77","spread":"26.119"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.61","spread":"31.979"},{"groupId":"OG001","value":"-28.19","spread":"25.536"},{"groupId":"OG002","value":"-22.79","spread":"26.793"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.98","spread":"29.709"},{"groupId":"OG001","value":"-30.27","spread":"26.058"},{"groupId":"OG002","value":"-26.21","spread":"28.115"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.87","spread":"31.013"},{"groupId":"OG001","value":"-31.75","spread":"25.615"},{"groupId":"OG002","value":"-25.21","spread":"26.317"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100","description":"Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.67","spread":"27.106"},{"groupId":"OG001","value":"-27.16","spread":"25.662"},{"groupId":"OG002","value":"-26.24","spread":"25.113"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.05","spread":"26.411"},{"groupId":"OG001","value":"-31.38","spread":"25.449"},{"groupId":"OG002","value":"-28.70","spread":"24.635"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.70","spread":"28.632"},{"groupId":"OG001","value":"-30.98","spread":"26.650"},{"groupId":"OG002","value":"-30.68","spread":"25.305"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":246},"commonTop":["Alanine Aminotransferase Increased","Upper Respiratory Tract Infection","Aspartate Aminotransferase Increased","Nasopharyngitis","Bronchitis"]}}}